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(57) Abstract: The present invention relates to the synthesis of GPI-related surface antigens of the parasite Toxoplasma gondii (T. 
gondii) and the resulting products obtained. These synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as 
vaccine against toxoplasmosis, a diseases caused by infection with T. gondii. 
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Synthesis of Diverse Glycosylphosphatidylinositol Glycans 
from Toxoplasma gondii and their Application as Vaccines and Diagnostics 
The present invention relates to the synthesis of GPI-related surface antigens of the 
5 parasite Toxoplasma gondii (T. gondii) and the resulting products obtained. These 
synthetic compounds are suitable for diagnosis of toxoplasmosis, as well as vaccine 
against toxoplasmosis, a diseases caused by infection with T. gondii. 
Glycosylphosphatidylinositols (GPis) are complex glycolipids that are found in 
10 eukaryotic cells either attached to the C-terminus of proteins or in free form. These 
complex glycolipids feature a phosphoethanolamine unit connecting the C-terminus 
of the protein to the glycan, a conserved pseudopentasaccharide core of 
H2N(CH2)20P03H6Mana1 ~2Mana1 ~6Mana1 ~4GicNa1 ~6myo-lno1-0P03H and 
a lipid attached to the core glycan via a phosphodiester linkage. The conserved GPI 
15 structure can be further decorated by various substituents including additional 
phosphoethanolamine units, an additional fatty acid ester at C2 position of myo-
inositol and oligosaccharide branch at C3 or C4 of Manl. The constitutive identity of 
the lipid subunit is variable and may include diacylglycerols, alkylacylglycerols or 
ceramides, with chains of different length and varying degrees of unsaturation. When 
20 GPis are isolated from natural sources, they are often obtained as heterogeneous 
mixtures especially in respect to the glycan and lipid subunit. GPis isolated from 
different species and, in some cases, from different tissues of the same organism, 
feature significant structural differences. The primary biological role of GPis is to 
localize the attached protein to the outer surface of the plasma membrane bilayer. It 
25 is suggested that GPis are responsible for the association of anchored proteins with 
lipid rafts and are, thereby, involved in diverse processes such as regulation of innate 
immunity, protein trafficking, and antigen presentation. 
Toxoplasmosis is a parasitic disease caused by the protozoan Toxoplasma gondii 
(T. gondii). T. gondii is ubiquitous in all warm blooded animals, but the primary host 
30 is the family of Felidae. A third to a half of the human population will have a 
toxoplasmosis infection at some point in their lives, but very few have symptoms. 
During the first few weeks after exposure, the infection typically causes no symptoms 
or a mild, flu-like illness: swollen lymph nodes, high temperature or muscle aches. 
However in most immunocompetent patients, the infection enters a latent phase, 
35 during which only bradyzoites are present, forming cysts in nervous and muscle 
tissues. Thereafter, the parasite rarely causes any symptoms in otherwise healthy 
adults. Along with, immunosuppression reactivation of a latent infection may occur 
and manifests primarily as a toxoplasmic encephalitis. Therefore, anyone with a 
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compromised immune system is at risk. These individuals include those undergoing 
chemotherapy, people suffering from HIV/AIDS or other immune disorders and 
organ-transplant recipients. The parasite can cause encephalitis (inflammation of the 
brain) and neurologic diseases, and can affect the heart, liver, inner ears, and eyes. 
5 Furthermore, primary infection with T. gondii during pregnancy can lead to 
transmission of the parasite from the mother to the unborn child, leading to a 
congenital toxoplasmosis. Women infected before conception normally do not 
transmit toxoplasmosis to the fetus. Nevertheless, there are cases known in which 
women, who already had a latent toxoplasmosis, got reinfected during pregnancy 
10 with a highly virulent strain of T. gondii that caused congenital toxoplasmosis. 
Disease in neonates may be severe, particularly if acquired early in pregnancy. Even 
spontaneous abortion and stillbirth may occur. Other symptoms that may occur are: 
low birth weight, fever, jaundice, abnormalities of the retina, mental retardation, 
hydrocephalus, convulsions, and brain calcification. 
15 Universal screening of pregnant women for example is cost saving at an expected 
cost of $390 per child screened compared to an expected societal cost of congenital 
toxoplasmosis of $1010 per birth under the "no maternal screening". Countries such 
as France that have a high prevalence of toxoplasmosis already established a 
universal maternal screening program. With an estimated 4 million births per year in 
20 the U.S. nearly $2.5 billion could be saved annually compared to no maternal 
screening (PLoS Neg/ Trap Dis. 2011; 5(9), 1333). The diagnosis of toxoplasmosis 
can be done using a variety of methods. The difficulty lies in the length of time, which 
is needed and in determining whether the infection is acute or chronic (latent). Acute 
infection can best be verified by identifying T. gondii parasite or T. gondii DNA from 
25 the patient's blood. Congenital infection of fetuses can be identified by the presence 
of cysts in the placenta or fetus. Of particular interest is determining acute infection in 
pregnant women, due to the risk of congenital toxoplasmosis. An acute toxoplamosis 
is accompanied by a high titer of lgM and low levels of lgG antibodies against T. 
gondii in the blood of a patient. Since high lgM titers can be persistent and detectable 
30 for over one year after the primary infection, it is very difficult to distinguish a latent 
from an acute toxoplasmosis. There are effective diagnostic techniques that monitor 
changes in the mother's antibody expression over time, but quick diagnosis is greatly 
preferred because fetuses often rapidly become infected. The Robert-Koch-Institute 
recommends a serological diagnosis using three subsequently steps: 
35 
1. Toxoplasma-antibody screening test: The most commonly used serologic tests 
detect the presence of anti-T. gondii lgG antibodies. lgG antibodies can be detected 
with the Sabin-Feldman dye test (considered the gold standard), indirect fluorescent 
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antibody (IFA) or agglutination. If tests applied to specific total antibodies against T. 
gondii as well as to lgG antibodies are negative, then there is neither an infection, nor 
immunity. If the test for total antibodies is negative an infection can be ruled out. 
Because screening tests based on lgG used in the early phase of infection can still 
5 be negative, they must be supplemented especially in pregnant women with an lgM 
test. 
2. Toxoplasma lqM antibody test: If such test results are negative (but positive 
lgG-Ab test) it can be assumed that an inactive (latent) toxoplasma infection exists. 
10 Further studies are not required. If the test is positive further evaluation must be 
done, especially during pregnancy or if differentiated clinical symptoms exists. 
15 
3. Toxoplasma fact-finding process: This includes in particular the determination 
of the avidity of lgG antibodies, the lgA antibody detection, immunoblot and 
quantitative research methods. Such a further determination using PCR and 
histological tests is very expensive. 
Hence, the diagnosis of T. gondii infection, especially of acute toxoplasmosis during 
pregnancy, is still difficult and time consuming. Therefore, there is need for an 
20 effective diagnostic test, which allows a fast and reliable diagnosis. 
From epidemiological view, the prevention of infection is the most important. It is 
essential to prevent a primary infection during pregnancy. For this it is necessary to 
know whether there is immunity or not. So far, the only possibility for prevention is 
25 to avoid acquisition of T. gondii infection. These persons should avoid contact with 
materials that may be contaminated with cat feces and the contact with raw meat. 
The development of a vaccine based on a defined antigen against T. gondii, which 
produces a sterile immunity is therefore of highest interest. In the last 60 years, 
numerous studies aimed at developing a vaccine against T. gondii. However, all 
30 these approaches were based on live or inactivated parasites, purified or 
recombinant proteins, or plasmids encoding protein antigens, and failed to induce 
protection in mouse models. While some of these antigens increased survival in 
challenged mice and reduced brain cyst loads, they proved unsuccessful in inhibition 
of maternal-fetal transmission. 
35 
To meet these challenges, the inventors focused on another class of immunogenic 
molecules, the GPI anchors, contained by the cell membrane of T. gondii. The two 
GPis contained by the cell membrane of T. gondii differ only by the presence of an 
additional a-glucose (a-Gic) in the side chain. While one GPI is used as a membrane 
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anchor for proteins and surface antigens of the parasite, the GPI containing the 
additional o-Gle in the side chain is a free glycolipid on the plasma membrane and is 
also known as the low molecular weight antigen ofT. gondii that elicits a specific lgM 
immune response in humans during an acute toxoplasmosis. Both GPis of T. gondii 
5 stimulate the production of the cytokine TN F-a in macrophages. Hence, the GPis of 
T. gondii seem to be promising candidates for the development of a vaccine and a 
diagnostic test. 
The use of the GPis as antigens for the development of a vaccine against T. gondii 
10 eliminates the risk of causing toxoplamosis associated with a vaccine based on 
attenuated or inactivated parasites. Moreover, T. gondii displays a high antigenic 
variation and passes through various life cycles, for which reason protein-based 
vaccines could be rendered ineffective through mutations. Since the biosynthesis of 
carbohydrates is not template-driven, resistance against the vaccines of this 
15 invention is not expected. In addition, protein or DNA-based vaccines are very likely 
limited to induce protective immunity against all strains of the parasite, but the GPI 
containing the additional a-Gic on the side chain is most probably common in every 
genotype. 
20 Due to heterogeneity of GPis isolated from biological samples and their amphiphilic 
character, which renders purification of GPI structures challenging, homogeneous 
samples of these glycolipids are only accessible via chemical synthesis. Further 
literature shows that isolated GPI structures contain also other glycolipids, which 
could cause false positive results (Eur. J. Clin. Microbial. Infect. Dis., 2003, 22, 418). 
25 With this in mind, the inventors initiated a synthetic program to address the need for 
a diverse set of homogeneous GPis and their analogues as a basis for vaccines and 
diagnostic devices. 
Therefore, the objective of the present invention is to provide a synthesis of defined 
30 compounds derived from GPis of T. gondii, where the resulting products are suitable 
for use in a diagnostic test of toxoplasmosis and for covalent linkage to a carrier for 
use as a vaccine for humans and animals against diseases caused by infection with 
T. gondii. The vaccines described herein are directed against a large spectrum of 
parasite strains. Further preferred embodiments of the present invention are 
35 disclosed in the dependent claims, the description and the examples. 
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Description of the invention 
5 As used herein, the term "bifunctional linker" refers to a bifunctional molecule 
containing functional group X and functional group Y, wherein functional group X is 
capable of reacting with the terminal thiol group of the compounds of general formula 
(I) and the functional group Y is capable of reacting with a carrier. 
10 Saccharides are known by the person skilled in the art as Tl-2 (T cell independent-2) 
antigens and poor immunogens. Therefore, to produce a saccharide-based vaccine, 
said saccharides are linked or conjugated to a "carrier" to provide a conjugate, which 
presents an increased immunogenicity in comparison with the saccharide. As used 
herein, a carrier is a pharmacological or immunological agent that modifies the effect 
15 of other agents, such as an active agent or vaccine. The term "carrier" as used herein 
refers to a compound used as a carrier protein, to which a compound of general 
formula (I) is linked and which enhances the recipient's immune response to the 
compound of general formula (1). In a preferred embodiment, the term "carrier" as 
used herein refers to a glycosphingolipid with immunomodulatory properties, to which 
20 a compound of general formula (I) is linked and which enhances the recipient's 
immune response to the compound of general formula (I). 
The term "conventional pharmaceutically acceptable adjuvant" as used herein refers 
to an immunological adjuvant i.e. a material used in a vaccine composition that 
25 modifies or augments the effects of said vaccine by enhancing the immune response 
to a given antigen contained in the vaccine without being antigenically related to it. 
For the persons skilled in the art, classically recognized examples immunological 
adjuvants include, but are not restricted to oil emulsions (e.g., Freund's adjuvant), 
saponins, aluminium or calcium salts (e.g., alum), non-ionic block polymer 
30 surfactants, and many others. 
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Thus, the present invention relates to compounds of general formula (I) 
NH 
o=\ 
OH 
HO 
(I) 
5 wherein 
R represents -H, -CH3, -C2Hs, -C3H7, -CH(CH3)2, -C4Hg, 
-CH2-CH(CH3)2, -CH(CH3)-C2Hs, -C(CH3)3, -CsH11, -CH(CH3)-C3H7, 
-CH2-CH(CH3)-C2Hs, -CH(CH3)-CH(CH3)2, -C(CH3)2-C2Hs, 
-CH2-C(CH3)3, -CH(C2Hs)2, -C2H4-CH(CH3)2, -C5H13, -C3H5-CH(CH3)2, 
10 -C2H4-CH(CH3)-C2Hs, -CH(CH3)-C4H9, -Ph, -CH2-Ph, or 
OH 
HO 0 
HO 
R1 and R4 represent independently of each other -OH, or -OP(O)(OH)-O-X-NH2; 
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R3 represents -H, -OH, -NHCOCH3, 
-NHCOCH2CH2CH3 or -N3; 
5 R5 and R6 represent independently of each other -H, -L-SH, -(C2H40),CH2-SH 
or -(C2H40),C2H4-SH and R5 and R6 cannot be simultaneously -H; 
L represents a linker; 
1 0 and r is an integer from 1 to 40. 
Preferably one of R5 and R6 is hydrogen, and more preferably R6 is hydrogen. Thus, 
R2 represents preferably -S02(R5), -OS02(R5), -OS02(0R5), or -OP(O)(OR5)(0H). 
15 Instead of using the disclaimer in the definition of R5 and R6 , R5 and R6 can be 
defined as follows: R5 represents -L-SH, -(C2H40),CH2-SH or -(C2H40),C2H4-SH 
and R6 represents -H, -L-SH, -(C2H40),CH2-SH or -(C2H40),C2H4-SH. 
Preferred are compounds of general formula (1), wherein R and R1 to R4, L, X and r 
20 have the meaning as disclosed herein and especially the meanings as disclosed 
above and wherein R6 represents hydrogen and R5 represents -L-SH, 
-(C2H40),CH2-SH or -(C2H40),C2H4-SH and more preferred R5 represents 
-L-SH. 
25 Even more preferred are compounds of general formula (1), wherein R2 represents 
-S02(L-SH), -OS02(L-SH), -OS02(0-L-SH), or -OP(O)(O-L-SH)(OH) and still 
more preferred wherein R2 represents -OS02(0-L-SH), or -OP(O)(O-L-SH)(OH) 
and most preferred wherein R2 represents -OP(O)(O-L-SH)(OH). 
30 In above formula (1), L represents any suitable linker. Preferably L represents a 
linker containing up to 50 carbon atoms. Further preferred is that this linker L is 
linked through a carbon atom of the linker to the SH group and through the same or 
preferably another carbon atom of the linker to the -S02-, -OS02-, -OS02-0-
or the phosphate group -OP(0)(0-)(0-) in the residues -S02-L-SH, -OS02-L-
35 SH, -OS02-0-L-SH, -OP(O)(OH)(O-L-SH) or -OP(O)(O-L-SH)(O-L-SH). 
This carbon atom linked linker contains up to 50 carbon atoms and preferably up to 
40 carbon atoms and more preferably between 3 and 35 carbon atoms and most 
preferably between 5 and 30 carbon atoms. 
5 
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wherein 
L 1 and L 4 represent independently of each other -(CH2)n-, -(CH2)m-, 
-CHR7-(CH2)m-, -(CH2)n-CR7R8-(CH2)m-, -o-C5H4-, -m-C5H4-, -p-C5H4-; 
L 2 and L 5 represent independently of each other -(CH2)p-, -(CH2)q-, -CHR9-, 
-CR9R10- -0- -S- -CO- -COO- -0-CO- -NH-CO- -CO-NH-
, ' ' ' ' ' ' ' 
-NH-CO-NH-, -o-C5H4-, -m-C5H4-, -p-C5H4-, -NR11-, -CH=CH-; 
I 
I ' 
I 
I 
-------<:\ 
------0 -----D ------0 I ', R11 I I \ R11 R11 R11 
R11 I I 
----~- I I ----~ ------o----- --t R" N/ 
---- ~ 
R1/ 
' I I 
I R12 I 
10 L 3 represents -(CH2)r--, -(CH2)r--CR13R14-(CH2)s-, -o-C5H4-, -m-C5H4-, 
-p-C5H4-; 
Compounds of general formula (I) are more preferred, wherein R2 represents 
-S02(-L 1-L 2-L 3-SH), -OS02(-L 1-L 2-L 3-SH), -OS02(0-L 1-L 2-L 3-SH), or -
15 OP(O)(O-L 1-L 2-L 3-SH)(OH) and still more preferred wherein R2 represents -
OS02(0-L 1-L 2-L 3-SH), or -OP(O)(O-L 1-L2-L 3-SH)(OH) and most preferred 
wherein R2 represents -OP(O)(O-L 1-L 2-L 3-SH)(OH) and again even more 
preferred are compounds of general formula (1), wherein R2 represents 
-S02(-L1-L3-SH), -OS02(-L1-L3-SH), -OS02(0-L1-L3-SH), or 
20 -OP(O)(O-L 1-L 3-SH)(OH) and still more preferred wherein R2 represents 
-OS02(0-L 1-L 3-SH), or -OP(O)(O-L 1-L 3-SH)(OH) and most preferred wherein R2 
represents -OP(O)(O-L 1-L 3-SH)(OH) and again even more preferred are 
compounds of general formula (I), wherein R2 represents -S02(-L 1-SH), 
-OS02(-L 1-SH), -OS02(0-L 1-SH), or -OP(O)(O-L 1-SH)(OH) and still more 
25 preferred wherein R2 represents -OS02(0-L 1-SH), or -OP(O)(O-L 1-SH)(OH) and 
most preferred wherein R2 represents -OP(O)(O-L 1-SH)(OH). 
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In these compounds wherein R2 has the meaning as defined in the afore-mentioned 
paragraph it is moreover preferred that R1 represents -OH and/or that R4 represents 
-OP(O)(OH)-O-X-NH2 and especially -OP(O)(OH)-O-CH2-CH2-NH2. 
5 R7 to R10, R13 and R14 represent independently of each other -H, -NH2, -OH, 
-OCH3, -OC2Hs, -OC3H7, cyclo-C3Hs, cyclo-C4H7, 
cyclo-CsHg, cyclo-CsH11, cyclo-C7H13, cyclo-CsH1s, -Ph, -CH2-Ph, 
-CPh3, -CH3, -C2Hs, -C3H7, -CH(CH3)2, -C4Hg, -CH2-CH(CH3)2, 
-CH(CH3)-C2Hs, -C(CH3)3, -CsH11, -CH(CH3)-C3H7, -CH2-CH(CH3)-C2Hs, 
1 0 -CH(CH3)-CH(CH3)2, -C(CH3)2-C2Hs, -CH2-C(CH3)3, -CH(C2Hs)2, 
-C2H4-CH(CH3)2, -CsH13, -C3Hs-CH(CH3)2, -C2H4-CH(CH3)-C2Hs, 
-CH(CH3)-C4H9, -CH2-CH(CH3)-C3H7, -CH(CH3)-CH2-CH(CH3)2, 
-CH(CH3)-CH(CH3)-C2Hs, -CH2-CH(CH3)-CH(CH3)2, -CH2-C(CH3)2-C2Hs, 
-C(CH3)2-C3H7, -C(CH3)2-CH(CH3)2, -C2H4-C(CH3)3, -CH(CH3)-C(CH3)3, 
15 -CH=CH2, -CH2-CH=CH2, -C(CH3)=CH2, -CH=CH-CH3, -C2H4-CH=CH2, 
-C7H1s, -CsH17, -CH2-CH=CH-CH3, -CH=CH-C2Hs, -CH2-C(CH3)=CH2, 
-CH(CH3)-CH=CH, -CH=C(CH3)2, -C(CH3)=CH-CH3, -CH=CH-CH=CH2, 
-C3Hs-CH=CH2, -C2H4-CH=CH-CH3, -CH2-CH=CH-C2Hs, 
-CH=CH-C3H7, -CH2-CH=CH-CH=CH2, -CH=CH-CH=CH-CH3, 
20 -CH2NH2, -CH20H, -CH2-CH2NH2, 
-CsH4-0CH3, -CsH4-0H, -CH2-CH2-0CH3, -CH2-CH20H, -CH2-0CH3, 
-CH2-CsH4-0CH3, -CH2-CsH4-0H, 
R11 and R12 represent independently of each other cyclo-C3Hs, cyclo-C4H7, 
25 cyclo-CsHg, cyclo-CsH11, cyclo-C7H13, cyclo-CsH1s, -Ph, -CH2-Ph, -CPh3, 
-CH3, -C2Hs, -C3H7, -CH(CH3)2, -C4H9, -CH2-CH(CH3)2, 
-CH(CH3)-C2Hs, -C(CH3)3, -CsH11, -CH(CH3)-C3H7, -CH2-CH(CH3)-C2Hs, 
-CH(CH3)-CH(CH3)2, -C(CH3)2-C2Hs, -CH2-C(CH3)3, -CH(C2Hs)2, 
-C2H4-CH(CH3)2, -CsH13, -C3Hs-CH(CH3)2, -C2H4-CH(CH3)-C2Hs, 
30 -CH(CH3)-C4H9, -CH2-CH(CH3)-C3H7, -CH(CH3)-CH2-CH(CH3)2, 
-CH(CH3)-CH(CH3)-C2Hs, -CH2-CH(CH3)-CH(CH3)2, -CH2-C(CH3)2-C2Hs, 
-C(CH3)2-C3H7, -C(CH3)2-CH(CH3)2, -C2H4-C(CH3)3, -CH(CH3)-C(CH3)3, 
-CH=CH2, -CH2-CH=CH2, -C(CH3)=CH2, -CH=CH-CH3, -C2H4-CH=CH2, 
-C7H1s, -CsH17, -CH2-CH=CH-CH3, -CH=CH-C2Hs, -CH2-C(CH3)=CH2, 
35 -CH(CH3)-CH=CH, -CH=C(CH3)2, -C(CH3)=CH-CH3, -CH=CH-CH=CH2, 
-C3Hs-CH=CH2, -C2H4-CH=CH-CH3, -CH2-CH=CH-C2Hs, 
-CH=CH-C3H7, -CH2-CH=CH-CH=CH2, -CH=CH-CH=CH-CH3, 
-CH2NH2, -CH20H, -CH2-CH2NH2, 
wo 2014/016317 PCT/EP2013/065559 
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-C5H4-0CH3, -C5H4-0H, -CH2-CH2-0CH3, -CH2-CH20H, -CH2-0CH3, 
-CH2-C6H4-0CH3, -CH2-C5H4-0H, 
n, m, rand s represent independently of each other an integer from 1 to 20; 
5 p and q represent independently of each other an integer from 0 to 5. 
10 
The compounds of the general formula (I) are capable of evoking a very specific 
immune response in such a way that antibodies are produced in a host, which do not 
show any significant cross activities to other related compounds. 
Further, the compounds of the general formula (I) are particular useful since these 
compounds are designed of being capable of binding to a carrier useful in 
vaccination, ensuring the correct orientation of the glycan in presence of free amine 
groups, which are characteristic to GPis. The correct orientation of the glycan in 
15 presence of free amine is ensured by the substituent(s) R5 and/or R6 that present a 
terminal thiol group. The free terminal thiol group is more nucleophilic than the free 
amines under neutral or acid pH conditions, which are specific to the conjugation 
reaction, and therefore ensures natural orientation of the glycan on the carrier. This 
is a major advantage of using the terminal thiol group over, for instance, an amino or 
20 hydroxyl group. 
25 
30 
Preferred substituents for R are: -H and 
Preferred substituents R3 are: -NH2, -OH, and -NHCOCH3. 
Preferred 
-C2H4-SH, 
substituents 
-C3H5-SH, 
for R5 and 
-C4Hs-SH, 
R6 are: 
-CsH10-SH, 
-CH2-SH, 
-C6H12-SH, 
-C7H14-SH, -CsH16-SH, -CgH1s-SH, -C10H2o-SH, 
-CH=CH-SH, -C(=O)-(CH2)n-SH, more preferred -CsH10-SH, -C6H12-SH, and 
-C7H14-SH, and most preferred -C6H12-SH. 
Further, in a preferred embodiment of the compounds of formula (I) according to the 
present invention R represents -H. 
5 
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A further preferred embodiment of the present invention refers to compounds of 
formula (I) wherein R represents 
In another preferred embodiment of the compounds of formula (I) according to the 
present invention R1 represents -OH. More preferred are compounds of general 
formula (1), wherein R1 represents -OH and R represents -H. 
10 In a particularly preferred embodiment of the compounds of formula (I) according to 
the present invention R2 represents -OP(O)(OR5)(0R6), wherein R5 represents -H, 
and R6 represents -C6H12-SH. 
15 
Thus, especially preferred are compounds of the formula (II) and (Ill): 
H~ro, 
HO~ 
HO 
HO 
t\:o 
HO~O 
NH 0=\ 
0 
OH 
0 0 
HO OH 
HO 0 OH 
' / 
/".. /'...... /'- /p~ 
HSy "-../ 'V 0 0 
and 
(II) 
wo 2014/016317 
H2N~0, OH 
...-:P,..... 
::~ro, 
HO~ 
HO 
t\:o 
HO~O 
NH 
o===\ 
0 
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(Ill) 
wherein the substituents R1, R3 and R4 in (II) and R1 and R3 in (Ill) have the meanings 
as defined herein. 
In the formulae (II) and (Ill) 
R represents preferably 
-H or 
OH 
5 The compounds falling under general formula (I) - (Ill) are novel so that the present 
invention relates also to compounds of general formula (I) - (Ill), as well as 
stereoisomers, mixtures of enantiomers, mixtures of diastereomers, tautomers, 
hydrates, solvates and racemates and pharmaceutically acceptable salts of these 
compounds. 
10 
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In yet another preferred embodiment of the present invention, the compound 
according to the general formula (I) is selected from the group comprising or 
consisting of: 
5 6-0-(aminoethyl phosphono )-a-o-man nopyranosyl-( 1 ~2)-a-o-man nopyranosyl-
( 1 ~6 )-4-0-( a-o-glucopyranosyl-( 1 ~4 )-2-deoxy-2-acetamido-13-D-galactopyranosyl )-
a-o-manno-pyranosyl-(1 ~4)-2-amino-2-deoxy-a-o-glucopyranosyl-(1 ~6)-1-0-
(thiohexyl phosphono )-o-m yo-inositol 
1 0 6-0-( am inoethyl phosphono )-a-o-mannopyranosyl-( 1 ~2)-a-o-mannopyranosyl­
( 1 ~6 )-(2-0-( aminoethyl phosphono )-4-0-( a-o-glucopyranosyl-( 1 ~4 )-2-deoxy-2-
acetam ido-13-D-galactopyranosyl) )-a-o-manno-pyranosyl -( 1 ~4 )-2-amino-2-deoxy-a-
o-glucopyranosyl-(1 ~6)-1-0-(thiohexyl phosphono)-o-myo-inositol 
15 a-o-mannopyranosyl-(1 ~2)-a-o-mannopyranosyl-(1 ~6)-(2-0-(aminoethyl 
phosphono )-4-0-(a-o-glucopyranosyl-(1 ~4 )-2-deoxy-2-acetamido-13-D-
galactopyranosyl) )-a-o-manno-pyranosyl -( 1 ~4 )-2-amino-2-deoxy-a-o-
glucopyranosyl-(1 ~6)-1-0-(thiohexyl phosphono )-o-m yo-inositol 
20 6-0-(aminoethyl phosphono )-a-o-mannopyranosyl-( 1 ~2)-a-o-mannopyranosyl­
(1 ~6)-4-0-( 2-deoxy-2-acetamido-13-D-galactopyranosyl) -a-o-manno-pyranosyl -
(1 ~4 )-2-amino-2-deoxy-a-o-glucopyranosyl-(1 ~6)-1-0-(thiohexyl phosphono)-D-
myo-inositol 
25 6-0-( am inoethyl phosphono )-a-o-mannopyranosyl-( 1 ~2)-a-o-mannopyranosyl-
( 1 ~6 )-(2-0-( aminoethyl phosphono )-4-0-( 2-deoxy-2-acetamido-13-D-
galactopyranosyl) )-a-o-manno-pyranosyl -( 1 ~4 )-2-amino-2-deoxy-a-o-
glucopyranosyl-(1 ~6)-1-0-(thiohexyl phosphono )-o-m yo-inositol 
30 a-o-mannopyranosyl-(1 ~2)-a-o-mannopyranosyl-(1 ~6)-(2-0-(aminoethyl 
phosphono )-4-0-( 2-deoxy-2-acetam ido-13-D-galactopyranosyl) )-a-o-manno-
pyranosyl -(1 ~4)-2-amino-2-deoxy-a-o-glucopyranosyl-(1 ~6)-1-0-(thiohexyl 
phosphono )-o-m yo-inositol 
35 
Another aspect of the present invention relates to a method for synthesis of a 
compound of formula (I) according to the following procedures: 
a) providing a compound of the general formula (IV) 
wo 2014/016317 
OPG4 
PG40 
PG40 t\:: 
PG40~0 
NH 
0===\ 
wherein 
0 
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O OPG3 
(IV) 
R represents -H, -CH3, -C2Hs, -C3H7, -CH(CH3)2, -C4Hg, 
5 -CH2-CH(CH3)2, -CH(CH3)-C2Hs, -C(CH3)3, -CsH11, -CH(CH3)-C3H7, 
-CH2-CH(CH3)-C2Hs, -CH(CH3)-CH(CH3)2, -C(CH3)2-C2Hs, 
-CH2-C(CH3)3, -CH(C2Hs)2, -C2H4-CH(CH3)2, -C6H13, -C3H5-CH(CH3)2, 
-C2H4-CH(CH3)-C2Hs, -CH(CH3)-C4H9, -Ph, -CH2-Ph, or 
OPG4 
1 0 R3 represents -N3, and 
PG3 to PG5 represent suitable protecting groups for hydroxyl functional 
groups; 
b) introducing the substituent R2 by reacting a compound of step a) with an 
acid derivative selected from H-S02(0R5') or H-P(O)(OR5 ')(0R6') or a 
15 salt thereof, 
wo 2014/016317 PCT/EP2013/065559 
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wherein R5' and R6' represent independently of each other -H, 
-CH2-S-PG6 , -C2H4-S-PG6 , -C3Hs-S-PG6 , -C4Hs-S-PG6 , 
-CsH10-S-PG6 , -CsH12-S-PG6 , -C7H14-S-PG6 , -CsH1s-S-PG6 , 
-CgH1s-S-PG6 , -C10H2o-S-PG6 , -CH=CH-S-PG6 , 
5 -C(=O)-(CH2)n-S-PG6 and R5' and R6' are not simultaneously -H, wherein 
PG6 is a suitable protecting group for a thiol, 
c) introducing the substituent R4 by removing PG5 or by removing PG5 and 
subsequent conversion with an acid of the formula 
H-P(O)(OH)-O-C2H4-NH(PG7) or a salt thereof, wherein PG7 is a suitable 
1 0 protecting group for an amine; 
d) introducing the substituent R1 by removing PG3 or by removing PG3 and 
subsequent conversion with an acid of the formula 
H-P(O)(OH)-O-C2H4-NH(PG7) or a salt thereof, wherein PG7 is a suitable 
protecting group for an amine; 
15 e) deprotecting the compound of step d) by removing the protection groups 
20 
PG4, PG6 and PG7 resulting in a compound of formula (I) 
HO 
HO 
0 
ks::o o 
HO~O 
NH 0=\ 
(I). 
0 
OH 
R3~0 0 OH 
R2 OH 
wherein R, R1 - R4 have the meanings as defined herein, 
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and wherein the steps c) and d) can be performed consecutively in the row c) 
and then d) or d) first and then c) thereafter or simultaneously. 
The protecting groups PG3, PG4, PG5 , PG6 and PG7 are commonly used protecting 
5 groups in organic synthesis, preferably for amines, hydroxyl groups, thiols, imines, 
carbonyls or other common functional groups. 
More specifically, PG3, PG4 and PG5 preferably are suitable protecting groups for 
hydroxyl groups, more preferably different suitable protecting groups for hydroxyl 
10 groups capable of being removed subsequently one after another by a suitable 
sequence of deprotection reactions. Preferred protection groups for hydroxyl groups 
are benzyl, benzoyl, 4-0-p-methoxybenzyl, allyl, acetyl, 
methylsulfonylethoxycarbonyl, levulinyl, dimethoxytrityl, 2-naphthylmethyl, 
triisopropylsilyl, terl-butyldimethylsilyl, terl-butyldiphenylsilyl, 2-trimethyl-
15 silylethoxymethyl. More specifically, in a preferred embodiment of the present 
invention protecting group PG3 may be levulinyl, protecting group PG4 may be benzyl 
and protecting group PG5 may be triisopropylsilyl. 
Preferred protecting groups for amines form carbamates such as terl-butyloxy 
carbonyl, 9-fluorenylmethyl carbonyl, allyl carbonyl, trichloroethyl carbonyl, 
20 benzylcarboxy carbonyl; or form amides such as acetyl or trichloro acetyl. In a 
preferred embodiment of the present invention protecting group PG7 is a 
benzylcarboxy carbonyl group. 
Also, protecting groups for hydroxyl groups may serve as well as protecting groups 
25 for thiols. Therefore, preferred protecting groups for thiols groups are benzyl, 
benzoyl, 4-0-p-methoxybenzyl, allyl, acetyl, methylsulfonylethoxycarbonyl, levulinyl, 
dimethoxytrityl, 2-naphthylmethyl, triisopropylsilyl, terl-butyldimethylsilyl, terl-
butyldiphenylsilyl, 2-trimethylsilylethoxymethyl. Specifically, in a preferred 
embodiment of the present invention protecting group PG6 is a benzyl group. 
30 
According to the present invention steps c) and d) are not supposed of being strictly 
performed in the order that step c) is accomplished before step d) is performed. 
Therefore, in one embodiment of the present invention step c) is performed before 
step d). In another embodiment of the present invention step d) is first performed and 
35 afterwards step c) is conducted. Thus, step c) is performed after step d). Therefore, 
these are two options wherein steps c) and step d) are performed consecutively. 
However, in another preferred embodiment of the present invention step c) and step 
d) are performed simultaneously. In such embodiment protection groups PG3 and 
PG5 are removed together and then optionally, substituents R1 and R4 being 
wo 2014/016317 PCT/EP2013/065559 
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H-P(O)(OH)-O-C2H4-NH(PG7) or a salt thereof with PG7 having the meaning as 
defined herein, are introduced at the same time. 
In case the compounds of the present invention bear basic and/or acidic substituents, 
5 they may form salts with organic or inorganic acids or bases. Examples of suitable 
acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, 
sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, 
salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic 
acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic 
10 acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, 
pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic 
acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic 
acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sulfanilic 
acid, camphorsulfonic acid, china acid, mandelic acid, o-methylmandelic acid, 
15 hydrogen-benzenesulfonic acid, picric acid, adipic acid, d-o-tolyltartaric acid, tartronic 
acid, (o, m, p)-toluic acid, naphthylamine sulfonic acid, and other mineral or 
carboxylic acids well known to those skilled in the art. The salts are prepared by 
contacting the free base form with a sufficient amount of the desired acid to produce 
a salt in the conventional manner. 
20 
Examples for suitable inorganic or organic bases are, for example, NaOH, KOH, 
NH40H, tetraalkylammonium hydroxide, lysine or arginine and the like. Salts may be 
prepared in a conventional manner using methods well known in the art, for example 
by treatment of a solution of the compound of the general formula (I) with a solution 
25 of an acid, selected out of the group mentioned above. 
Further, it is also possible that the compounds of the present invention bear 
simultaneously basic and acid groups. Further, it may also occur that these basic and 
acid groups appear to be in close vicinity to one another enabling an intramolecular 
30 proton transfer from the acidic group the basic group. Therefore, in a preferred 
embodiment of the present invention the compound of the formula (I) may be zwitter-
ionic, bearing at least e.g. one -o- and one -NH3+ group. 
Some of the compounds of the present invention may be crystallised or recrystallised 
35 from solvents such as aqueous and organic solvents. In such cases solvates may 
be formed. This invention includes within its scope stoichiometric solvates including 
hydrates as well as compounds containing variable amounts of water that may be 
produced by processes such as lyophilisation. 
5 
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The possibility of a synthesis of the compounds according to formula (I) enables 
production of sufficient and pure amounts of the desired GPI structure, which may 
support research towards understanding of the pathomechanism of T. gondii 
infection and enables designing a vaccine against T. gondii. 
Surprisingly it was found that the compounds of general formula (I) are suitable to 
raise an immune response in an animal, and are suitable for vaccination against 
infectious diseases. Therefore, another aspect of the present invention relates to the 
use of a compound of general formula (I) for vaccination against toxoplasmosis. One 
10 embodiment of the invention is further a compound of the general formula (I) for 
vaccination against an infection with T. gondii. The invention relates also to the use 
of a compound of general formula (I) for the manufacture of a vaccine against 
toxoplasmosis. 
15 Further was found that extraordinary potent and stable vaccine can be derived when 
a compound of general formula (I) is covalently linked to a carrier through the 
terminal thiol group, preferably as thio ether or thio ester. Saccharides are known by 
the person skilled in the art as Tl-2 (T cell independent-2) antigens and poor 
immunogens. Therefore, to produce a saccharide-based vaccine, said saccharides 
20 are linked or conjugated to a "carrier" to provide a conjugate, which presents an 
increased immunogenicity in comparison with the saccharide. Thus, a compound of 
general formula (I) is linked to a carrier through the terminal thiol group to provide a 
conjugate consisting on the compound of general formula (I) covalently linked to a 
carrier. 
25 
The immune response raised against the conjugate consisting of compound 3 
covalently linked to CRM197 clearly recognized the parasite (see Figure 4, 
immunofluorescence picture). Analysis of the polyclonal antibodies revealed that the 
immune response against the conjugate was very specific. The serum antibodies 
30 bound compound 3, but did not show cross reactivity to the structurally close related 
compound 5, which is a mammalian structure (see Figure 3). It is important to note 
that compound 3 does not induce cross-reactivity to human structures, which 
excludes the possibility of raising an autoimmune response. 
35 The immune response raised against the conjugate consisting of compound 4 
covalently linked to CRM197 clearly recognized the parasite and located the GPI at 
the apical end of the parasitic cell (see Figure 13, immunofluorescence picture). 
These findings are very important because the apical complex ofT. gondii is used for 
invading host cells. Induction of an immune response against this site of the parasite 
wo 2014/016317 PCT/EP2013/065559 
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is capable of blocking the invasion mechanism of T. gondii. Together with the 
opsonizing properties of the raised antibodies, this vaccine can be capable of 
inducing immunity against this parasite. Analysis of the polyclonal antibodies 
revealed that the immune response against the conjugate was very specific. The 
5 serum antibodies bound compound 4, but did not show cross reactivity to 
substructures of this GPI carbohydrate (see Figure 12). 
The specific immune response both conjugates elicited show that only compounds 3 
and 4, presenting the full glycan structure, are able to induce the production of 
10 antibodies in vivo that are able to recognize the parasite T. gondii. Although 
WO 199701 0249 A 1 shows that substructures of GPI carbohydrate covalently 
attached to a carrier are sufficient to raise an immune response that recognizes the 
parasite T. gondii, our results indicate that these substructures of compound 4 (see 
Figure 12; one trisaccharide and two pentasaccharides with a varying degree of 
15 phosphorylation) seem not be sufficient, because they are not recognized by the 
polyclonal antibody response. 
The present invention relates therefore to a compound of general formula (I) 
covalently linked to a carrier. Particularly preferred is that said carrier is a peptidic 
20 compound and even more preferred a bacterial peptide or a compound derived from 
a bacterial peptide. In another preferred embodiment, said carrier is a 
glycosphingolipid with immunomodulatory properties. 
As used herein, a carrier is a pharmacological or immunological agent that modifies 
25 the effect of other agents, such as an active agent or vaccine. The term "carrier" as 
used herein refers to a compound used as a carrier protein, to which a compound of 
general formula (I) is linked and which enhances the recipient's immune response to 
the compound of general formula (1). In a preferred embodiment, the term "carrier" as 
used herein refers to a glycosphingolipid with immunomodulatory properties, to which 
30 a compound a compound of general formula (I) is linked and which enhances the 
recipient's immune response to the compound of general formula (1). 
It is preferred that the carrier to which the compound of general formula (I) is 
covalently linked is a carrier protein. For the person skilled in the art, a carrier protein 
35 is a protein selected from the group comprising or consisting of: a diphtheria toxoid, a 
mutated diphtheria toxoid, a modified diphtheria toxoid, a mutated and modified 
diphtheria toxoid, a tetanus toxoid, a modified tetanus toxoid, a mutated tetanus 
toxoid, outer membrane protein (OMP), bovine serum albumin (BSA), keyhole limpet 
hemocyanine (KLH) or cholera toxoid (CT). 
wo 2014/016317 PCT/EP2013/065559 
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It is particularly preferred that the carrier to which the compound of general formula 
(I) is covalently linked, is selected from the group comprising or consisting of: a 
diphtheria toxoid, a mutated diphtheria toxoid, a modified diphtheria toxoid, a mutated 
5 and modified diphtheria toxoid, a tetanus toxoid, a modified tetanus toxoid or a 
mutated tetanus toxoid. The term "toxoid" as used herein refers to a bacterial toxin 
(usually an exotoxin) whose toxicity has been inactivated or suppressed either by 
chemical (formalin) or heat treatment, while other properties, typically 
immunogenicity, are maintained. A mutated toxoid as used herein is a recombinant 
10 bacterial toxin, which has been amended to be less toxic or even non-toxic by 
amending the wild-type amino acid sequence. Such a mutation could be a 
substitution of one or more amino acids. A modified toxoid, as used herein, is a 
bacterial toxoid, on which a functional group X has been introduced by reacting said 
bacterial toxoid with a bifunctional linker. Thus, the modified toxoid presents a or is 
15 modified with functional group X, said functional group X being capable of reacting 
with the terminal thiol group of the compounds of general formula (1). The term 
"bifunctional linker" refers to a bifunctional molecule containing functional group X 
and functional group Y, wherein functional group X is capable of reacting with the 
terminal thiol group on the compounds of general formula (I) and the functional group 
20 Y is capable of reacting with a carrier. It is especially preferred that the compound of 
general formula (I) is covalently linked to the non-toxic mutated diphtheria toxin 
CRM197, which is modified with the functional group X. Preferably, the compound of 
general formula (I) is covalently linked to the non-toxic mutated diphtheria toxin 
CRM197, which is modified with maleimide. In the most preferred embodiment, the 
25 compound of general formula (I) is covalently linked to the non-toxic mutated 
diphtheria toxin CRM197, which is modified with a-iodoacetamide. 
CRM197 like wild-type diphtheria toxin is a single polypeptide chain of 535 amino 
acids (58 kD) consisting of two subunits linked by disulfide bridges having a single 
30 amino acid substitution of glutamic acid for glycine. It is used as a carrier protein in 
a number of approved conjugate vaccines, such as the pneumococcal vaccine 
Prevnar 13® (Pfizer Inc.). 
In one aspect of the present invention the compounds of the formula (I) are 
35 covalently linked to a carrier for the use in a vaccine. The binding or covalent linkage 
to the carrier can be accomplished by first providing a suitable carrier capable of 
stimulating the immune system's response to a target antigen, but does not in itself 
confer immunity as defined above. Examples of suitable carriers include, but they 
are not restricted to peptidic compounds, bacterial peptides, compounds derived from 
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a bacterial peptides, mutated toxoids and glycosphingolipids with immunomodulatory 
properties. 
In a preferred embodiment of the present invention such a suitable carrier may be 
5 CRM197. Said suitable carriers are able to react with the functional group Y of the 
bifunctional linker to provide a carrier modified with a functional group X. In a 
preferred embodiment of the present invention the carrier is modified by at least one 
functional group X of the group comprising or consisting of maleimide; a-iodoacetyl; 
a-bromoacetyl; N-hydroxysuccinimide ester (NHS), 2-pyridyldithiols, thiol and vinyl 
10 (see also Figure 5A). The introduction of such functional group X on the carrier is 
preferably accomplished by reaction of a suitable carrier with a bifunctional linker that 
bears on one side the functional group Y prone of reacting with the suitable carrier 
and on the other side a functional group X prone to react with the terminal thiol group 
of the compounds of general formula (I). 
15 
In a preferred embodiment of the present invention such a bifunctional linker bears 
on one side a vinyl functional group X prone to react with the terminal thiol group of 
the compound of general formula (1), and on the other side a N-hydroxysuccinimide 
ester functional group Y that is prone of reacting with lysine side amino group of a 
20 peptidic compound. 
In another preferred embodiment of the present invention such a bifunctional linker 
bears on one side a maleimide functional group X prone to react with the terminal 
thiol group of the compound of general formula (1), and on the other side a N-
25 hydroxysuccinimide ester functional group Y that is prone of reacting with lysine side 
amino group of a peptidic compound. 
Preferably, such a bifunctional linker bears on one side an a-iodoacetyl functional 
group X prone to react with the terminal thiol group of the compound of general 
30 formula (1), and on the other side a N-hydroxysuccinimide ester functional group Y 
that is prone of reacting with lysine side amino group of a peptidic compound. 
In another embodiment, said carrier is preferably a glycosphingolipid with 
immunomodulatory properties, and more preferably (2S,3S,4R)-1-( a-D-
35 galactopyranosyl )-2-hexacosanoylam inooctadecane-3,4-d iol. 
The term glycosphingolipid with immunomodulatory properties, as used herein, refers 
to a suitable glycosphingolipid capable of stimulating the immune system's response 
to a target antigen, but which does not in itself confer immunity as defined above. 
wo 2014/016317 PCT/EP2013/065559 
22 
Glycoshingolipids as used herein are compounds containing a carbohydrate moiety 
a-linked to a sphingolipid. Preferably, the carbohydrate moiety is a hexopyranose 
and most preferably is a-o-galactopyranose. For the person skilled in the art, 
sphingolipids are a class of lipids containing a C18 amino alcohol connected via an 
5 amide bond to a fatty acid. The C18 amino alcohol is preferably mono-, di- or 
polysubstituted with hydroxyl groups. Especially preferred, the C18 amino alcohol is 
phytosphingosine. The fatty acid is preferably a monocarboxylic acid having a 
saturated alkyl chain of a number of carbons ranging from 16 to 28 and more 
preferably from 18 to 26. Glycosphingolipids with immunomodulatory properties 
10 include, but they are not restricted to (2S,3S,4R)-1-(a-o-galactopyranosyl)-2-
hexacosanoylaminooctadecane-3,4-diol, which can stimulate natural killer (NK) 
activity and cytokine production by natural killer T (NKT) cells and exhibits potent 
antitumor activity in vivo (Proc. Nat/ Acad. Sci. USA, 1998, 95, 5690). 
15 The conjugates of the compounds of general formula (I) to the glycosphingolipid with 
immunomodulatory properties have the advantage of being heat stable. To be 
suitable for covalent linkage to the compounds of general formula (1), on the 
glycosphingolipid with immunomodulatory properties a functional group X is 
introduced by reacting the glycosphingolipid with immunomodulatory properties with 
20 a bifunctional linker. Thus, a modified glycosphingolipid with immunomodulatory 
properties presents or is modified with a functional group X prone to react with the 
terminal thiol group of the compounds of general formula (I) preferably by formation 
of a covalent bond. Preferably, the glycosphingolipid with immunomodulatory 
properties is modified at the C6 of the carbohydrate moiety. In a preferred 
25 embodiment of the present invention the carrier is modified by at least one functional 
group X of the group comprising or consisting of maleimide, a-iodoacetyl, a-
bromoacetyl, N-hydroxysuccinimide ester (NHS), 2-pyridyldithiols, thiol and vinyl (see 
also Figure 5A). The introduction of such functional group X on the glycosphingolipid 
with immunomodulatory properties is preferably accomplished by reaction of a 
30 suitable glycosphingolipid with immunomodulatory properties with a bifunctional 
linker that bears on one side a functional group X prone of reacting with the terminal 
thiol group of the compound of general formula (I) and on the other side a functional 
group Y that is prone to react with the glycosphingolipid with immunomodulatory 
properties. 
35 
In a preferred embodiment of the present invention such a bifunctional linker bears 
on one side a-iodoacetyl functional group X prone to react with the terminal thiol 
group of a compound of general formula (1), and on the other side a N-
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hydroxysuccinimide ester functional group Y that is prone of reacting with an amino 
group of a glycosphingolipid with immunomodulatory properties. 
In another preferred embodiment of the present invention such a bifunctional linker 
5 bears on one side maleimide functional group X prone to react with the terminal thiol 
group of a compound of general formula (1), and on the other side a N-
hydroxysuccinimide ester functional group Y that is prone of reacting with an amino 
group of a glycosphingolipid with immunomodulatory properties. 
10 Preferably, such a bifunctional linker bears on one side vinyl functional group X prone 
to react with the terminal thiol group of a compound of general formula (1), and on the 
other side N-hydroxysuccinimide ester functional group Y that is prone of reacting 
with an amino group of a glycosphingolipid with immunomodulatory properties. 
15 For the preferred embodiment wherein the carrier is modified with a vinyl functional 
group X, a compound of the formula (I) can be covalently linked to the vinyl functional 
group X by a thiol-ene reaction by means of irradiation with UV light and/or in the 
presence of an initiator to form a stable thioether bond (see also Figure 5b). 
20 For the preferred embodiment wherein the carrier is modified with a maleimide 
functional group X, the terminal thiol group of a compound of general formula (I) adds 
via a Michael addition to the maleimide moiety. 
For the preferred embodiment wherein the carrier is modified with a a-iodo-
25 acetamide functional group X, the terminal thiol group of a compound of the formula 
(I) substitutes the iodide of the a-iodo-acetyl moiety. 
Further, in the preferred embodiments wherein the carrier is a protein carrier, these 
functionalization reactions are performed in such a way that more than one functional 
30 group X is introduced on the carrier. Thus, the said protein carrier presents or is 
modified with more than one functional group X. However, it is also possible that just 
one functional group X is introduced on the carrier. In a preferred embodiment of the 
present invention the number of functional groups X introduced on the carrier after 
the functionalization reaction ranges preferably from 5 to 100, more preferably from 
35 10 to 50, and most preferably from 10 to 40. After the carrier was modified with 
functional group X by one said functionalization reactions, the compounds of the 
present invention are added in order to bind the terminal thiol group, e.g. to the 
maleimide double bond by an addition-like reaction. Therein, it is possible to adjust 
the number of molecule of the formula (I) being linked to the carrier. The number of 
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molecules of the formulas (I) being linked to the carrier can range preferably from 1 
to 1 00, more preferably from 3 to 50, and most preferably from 5 to 15. In a preferred 
embodiment the number of molecules of the formulas (I) being linked to a carrier 
ranges from 1 to 15, more preferably from 2 to 1 0 and especially preferred from 3 to 
5 7. 
Another aspect of the present invention relates to the use of the compound of 
general formula (I) covalently linked to a carrier for vaccination against 
toxoplasmosis. One embodiment of the invention is further a compound of the 
10 general formula (I) covalently linked to a carrier for vaccination against an infection 
with T. gondii. The invention relates also to the use of a compound of general formula 
(I) covalently linked to a carrier for the manufacture of a vaccine against 
toxoplasmosis. 
15 The examples of the present invention show that the compounds of general formula 
(I) linked to a carrier elicited a highly specific antibody response to the compounds of 
general formula (I) in mice, including isotype switching and affinity maturation (see 
example 14 and example 15). Moreover, the generated antibodies recognized the 
natural GPI on the parasite (see example 16). 
20 
Another aspect of the present invention relates to pharmaceutical formulations and 
pharmaceutical compositions for vaccination containing a compound of general 
formula (I) optionally covalently linked to a carrier as an active ingredient, together 
with at least one pharmaceutically acceptable carrier, excipient, solvent and/or 
25 diluents. 
Further preferred, the pharmaceutical composition is formulated in the form of a 
lyophilisate or liquid buffer solution. 
30 The compound of general formula (I) optionally covalently linked to a carrier can also 
be administered in form of its pharmaceutically active salt optionally using 
substantially nontoxic pharmaceutically acceptable carrier, excipients, adjuvants or 
diluents. The pharmaceutical composition, which is used as a vaccine is prepared in 
a conventional solid or liquid carrier or diluents and may comprise a conventional 
35 pharmaceutically acceptable adjuvant at suitable dosage level in a known way. 
Classically recognized examples of conventional pharmaceutically acceptable 
adjuvants include oil emulsions (e.g., Freund's adjuvant), saponins, aluminium or 
calcium salts (e.g., alum), non-ionic block polymer surfactants, and many others. 
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The inventive pharmaceutical composition may be administered by any appropriate 
means, including but not limited to inhalation, injection (intravenous, intraperitoneal, 
intramuscular, subcutaneous) by absorption through epithelial or mucocutaneous 
linings (oral mucosa, rectal and vaginal epithelial linings, nasopharyngial mucosa, 
5 intestinal mucosa); orally, rectally, transdermally, topically, intradermally, 
intragastrically, intracutaneously, intravaginally, intravasally, intranasally, 
intrabuccally, percutaneously, sublingually, or any other means available within the 
pharmaceutical arts. The compounds of the invention of the general formula (I) are 
present in said vaccine formulation in the range of 10 to 1000 IJg/g. 
10 
It was shown that the GPI of T. gondii containing the additional a-Gic in the side 
chain is identical with the known "low molecular weight antigen" of this parasite and 
lgM antibodies against this structure could be detected in sera from patients with 
toxoplasmosis (J. Bioi. Chem. 1992, 267, 11721.). The current ELISA-based 
15 diagnostic techniques in order to identify acute toxoplasmosis have a high rate of 
false-positive results because high lgM responses can be detected even more than a 
year after a primary infection. Moreover, so far isolates of the parasite are used as 
antigens for the test, and therefore their quality of production can vary extremely. In 
literature it has been shown that other glycolipids are included in these isolates, 
20 which is one of the reasons for false-positive results (J. Clin. Microbial. Infect. Dis. 
2003, 22, 418). Disadvantages of overtreatment of healthy and infected patients, 
especially pregnant women, who would require a stressful diagnosis and need 
medical treatment including Qyrimethamine, .§ulfadiazine, and folinic acid (PSF) after 
18 weeks of gestation, which are partially inhibitors of the enzyme dihydrofolate 
25 reductase and cause severe side effects such as cardiac arrhythmias and 
leukopenia, are obvious. Furthermore inhibition of the dihydrofolate reductase can 
lead to congenital malformations, including neural tube defects, which are of course 
harmful for the unborn child (PLoS Neg/ Trap Dis. 2011; 5(9), 1333). A test based on 
a single synthetic antigen is therefore a clear advantage over the commercially 
30 available diagnostic tools. 
Moreover the inventors could show that the compounds according to formula (I) can 
be used in immunological assays for diagnosis of diseases caused by T. gondii. 
Such assays comprise, for instance, microarray and ELISA useful for diagnosis of 
35 diseases caused by T. gondii. Therefore another aspect of the present invention 
refers to the use of a compound of formula (I) for diagnosis of toxoplasmosis. Thus, 
especially preferred embodiments of the present invention relate to pure synthetic 
compounds of formula (I) for diagnosis of toxoplasmosis. 
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It is preferred that the compound of formula (I) is used for diagnosis of acute 
toxoplasmosis. Acute toxoplasmosis is characterized by a high-titer of lgM in the 
serum of the patients and the fact that lgG is not present or only with a low-titer. It is 
preferred that the compound of formula (I) is used for the differential diagnosis of 
5 acute toxoplasmosis, that means that the compound of formula (I) is used in a 
diagnostic test which allows not only to determine if a patient is infected with 
T. gondii, but also to differentiate between an acute infection and a latent or chronic 
infection. 
1 0 Thus, one especially preferred embodiment of the present invention relates to the 
use of only one specific defined compound of formula (I) for diagnosis of 
toxoplasmosis. It is further preferred that the compound of formula (I) used for 
diagnosis of toxoplasmosis is substantially pure, having a purity of~ 95%, preferably 
~ 96%, more preferably ~ 97%, still more preferably ~ 98%, and most preferably ~ 
15 99%. In addition, the chemically synthesized compound of formula (I) does not 
have any microheterogenicity as the oligosaccharides from biological sources do. 
Nevertheless, the use of a mixture of different compounds of formula (I) for diagnosis 
of toxoplasmosis is possible, but is less preferred. 
20 There are different possibilities for the choice of an assay system in which a 
compound of formula (I) is used for diagnosis of toxoplasmosis. An assay conducted 
for diagnostic purposes according to the invention may be an immune assay like a 
solid-phase enzyme immunoassay (EIA), an enzyme linked immunosorbent assay 
(ELISA), especially an "indirect" ELISA, a radioimmune assay (RIA) or a fluorescence 
25 polarization immunoassay. For the use of a compound of formula (I) in such assays it 
could be necessary to immobilize the compound of formula (I) on a carrier material, 
preferably a solid carrier material. 
Therefore a compound of formula (I) may be immobilized on a carrier material, 
30 particularly for diagnostic applications. One preferred embodiment of the present 
invention is a compound of general formula (I) immobilized on a carrier material by 
covalent bonding. One particularly preferred embodiment of the present invention is a 
compound of general formula (I) immobilized on a carrier material by direct or indirect 
covalent bonding. Thereby direct covalent bonding is especially preferred. 
35 
There are also carrier materials commercially available made from polymers with 
reactive functional introduced for covalent bonding. One example are microplates 
named Covalink™ NH by Thermo scientific, which allow covalent binding through a 
secondary amine group. 
5 
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In a preferred embodiment the solid carrier material is selected from the group 
comprising or consisting of: glass slides, microtitre plates, test tubes, microspheres, 
nanoparticles or beads. 
It is particularly preferred that the carrier material is a glass slide or a microtitre plate. 
A microtitre plate or microplate or microwell plate, is a flat plate with multiple "wells" 
used as small test tubes. Typically a microtitre plate having 6, 24, 96, 384 or even 
1536 sample wells can be used. Microplates are produced from many different 
10 materials, like polycarbonate for microtitre plate used for PCR. The most common is 
polystyrene as used for most optical detection microplates. It can be colored white by 
the addition of titanium dioxide for optical absorbance or luminescence detection or 
black by the addition of carbon for fluorescent biological assays. 
15 "Direct covalent bonding" as used herein refers to immobilization of a compound of 
general formula (I) by reacting a functional group of the compound of general formula 
(I) with a functional group of the material the carrier material is made from. It is 
preferred that the functional group of the compound of general formula (I) is R2 as 
defined above. Possible reactive, functional groups of the carrier material may be: 
20 thiols, carbonyls, carboxyls, vinyls, halides such as fluorides, chlorides, bromides and 
iodides, maleimides, succinimide esters. 
"Indirect covalent bonding" as used herein refers to immobilization of a compound of 
general formula (I) on a carrier material, wherein the compound of general formula (I) 
25 is covalently linked to a second compound, which mediates the immobilization to the 
carrier material. It is preferred that this second compound is a protein, which does 
not cause an immune reaction. It is important that the second compound itself is 
most probably not bound by any antibody present in the blood or serum of a patient 
to avoid false positive results. Further the second compound should be able to be 
30 immobilized on the carrier material, by covalent or non-covalent bonding. It is 
preferred that this second compound is selected from the group comprising or 
consisting of bovine serum albumin (BSA), human serum albumin (HAS), gelatin or 
casein. The immobilization using indirect covalent bonding therefore refers 
preferably to covalent bonding of a compound of general formula (I) to a protein as a 
35 second compound (e.g. using the free amino groups of a protein) and subsequently 
binding of the protein to the carrier material by covalent bonding or non covalent 
interaction between the carrier material and the protein. Possible non-covalent 
interactions are: hydrogen bonds, ionic bonds, van der Waals forces, and 
hydrophobic interactions. Many polymers, such as polystyrene and polypropylene are 
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hydrophobic in nature. Nevertheless there are also manufacturers, which supply 
carrier materials having specialized surfaces optimized for different adhesion 
conditions. 
5 However, immobilization, especially using indirect covalent bonding, may also occur 
by strong adhesion. Thus, an effective immobilization according to the present 
invention may be realized not only by chemical bonding, but also unbound by 
immobilization related to physisorption. As key feature for physisorption acts the 
phenomenon that the force for adhesion is caused by van der Waals force. The term 
10 "unbonded" refers to a bonding other than covalent bonding. 
Chemisorption as immobilization form according to the present invention uses 
chemical bonds between the carrier material and a compound of formula (1). Such 
bond may be covalent, but may also be ionic. Compounds of the general formula (I) 
15 can therefore be covalently attached via chemisorption to for example gold or silver 
nanoparticles as well as surfaces consisting of those noble metals and CdSe 
quantum dots. 
In a preferred embodiment of the present invention immobilization of a compound of 
20 the formula (I) on a carrier material is realized by direct covalent bonding namely a 
chemical reaction between these two reactants, preferably by a substitution reaction. 
In a more preferred embodiment of the present invention the carrier material is 
modified with a functional group, which is capable of leaving the carrier material upon 
reaction with the compound of the present invention. Such functional group may be 
25 bound directly to a composing molecule of the carrier material or may be bound to a 
linker, which is directly bound to the composing molecule of the carrier material. 
Thus, in a more preferred embodiment of the present invention the carrier material is 
modified to bear a suitable leaving group. Suitable leaving groups may be halides 
such as chlorides, bromides and iodides, succinimide esters, and esters. Such 
30 leaving groups may be or may be incorporated in maleimide, a-iodoacetyl, a-
bromoacetyl, N-hydroxysuccinimide ester (NHS) and 2-pyridyldithiols. In yet more 
preferred embodiment, the leaving group on the carrier material is capable to 
preferably react with thiols, preferably upon proton exchange. In a preferred 
embodiment of the present invention the carrier material is functionalized with a 
35 succinimidyl hydroxide functional group, more preferably N-succinimidyl hydroxide, 
which will leave the carrier material upon reaction with a compound of the present 
invention as N-hydroxysuccinimide. 
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Modification of the carrier material by introduction of a suitable leaving group is 
preferably carried out by reaction of an unmodified carrier material with a reactive 
bifunctional molecule A, preferably a bifunctional molecule with a molecular bridge or 
spacer arm between the two functional groups: a functional group A 1 prone to react 
5 with the carrier material and a functional group A2, which is a suitable leaving group. 
In a preferred embodiment of the present invention functional groups A1 willingly 
reacting with the carrier material comprises sulfosuccinimide esters and 
succinimides. One further preferred aspect of the bifunctional molecules A is the 
ability of providing the functional group meant to bind with a compound of the formula 
10 (I) is an appropriate distance to the carrier material. Such an appropriate distance is 
provided by a molecular bridge or spacer arm of suitable length. Such a molecular 
bridge or spacer arm may have a length preferably from 3 A (1 o-10 m) to 10 nm, more 
preferably from 5 A to 50 A, and most preferably from 6 A to 30 A. Suitable reactive 
bifunctional molecules for modification of the carrier material comprise succinimidyl 
15 (4-iodoacetyl) aminobenzoate (sulfo-SIAB), succinimidyl-3-
(bromoacetamido)propionate (SBAP), disuccinimidyl glutarat (DSG), 2-pyridyldithiol-
tetraoxatetradecane-N-hydroxysuccinimide (PEG-4-SPDP) (see Figure 7). 
In a preferred embodiment the assay conducted for diagnostic purposes according to 
20 the invention is a fluorescence polarization assay. For such assay, the compound of 
general formula (I) is immobilized on a fluorescent carrier material. The compound of 
general formula (I) covalently bound to a fluorescent carrier material could be used 
for detection of antibodies in human sera specific to the compounds or general 
formula (I) by fluorescence polarization. Fluorescence polarization is a known 
25 powerful method for the rapid and homogeneous analysis of molecular interactions in 
biological and chemical systems. The principles of fluorescence polarization are 
based on the excitation of a fluorescent molecule with polarized light. This results in 
the emission of photons in the plane, which is parallel and perpendicular to the 
excitation plane and yields information about the local environment of the fluorescent 
30 molecule.The rotation of fluorescent molecule in solution can be observed by 
measuring the rotation of the plane of polarization of the light that was originally 
beamed in. The observed rotation depends on the rotation relaxation time and is only 
influenced by the temperature, the viscosity and the molecular weight of the 
fluorescent molecule. Thus, fluorescence polarization is a suitable method for 
35 measuring these parameters and in particular changes in these parameters. The 
term "fluorescent carrier material" as used herein refers to a compound that absorbs 
light energy of a specific wavelength and re-emits light at a longer wavelength. In a 
preferred embodiment, the fluorescent carrier material is fluorescein isothiocyanate 
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(FITC), which has an excitation/emission peak at 495/517 nm and can be coupled to 
the compounds of general formula (I) through the isothiocyanate group. 
Another aspect of the present invention is the use of a compound of general formula 
5 (I) immobilized on a carrier material by covalent bonding for diagnosis of 
toxoplasmosis. The diagnosis of acute toxoplasmosis is preferred. 
One embodiment of the present invention relates to a kit comprising at least one 
compound of general formula (I) immobilized on a carrier material by covalent 
10 bonding or the compound of general formula (I) for immobilization on a carrier. 
A kit in molecular biology or in medical diagnostics is a package, which includes all 
necessary ingredients for performing a certain method or singular step. Standard 
chemicals as present in any standard molecular biology or medical laboratory are 
15 normally not included. Nevertheless, some of these standard chemicals may be 
indispensable to carry out the diagnosis or the immobilization properly. It is 
understood that all ingredients are provided in quantities that allow for a proper 
execution of the desired reactions for the majority of scientific, diagnostic and 
industrial applications. 
20 
Often, but not always, these ingredients are provided in already prepared solutions 
ready- or close to ready-for-use. There may be also combinations of different 
ingredients already added together. A further advantage is that such kits use to be 
verified. Therefore the operator doesn't have to prove again the viability of the 
25 diagnostic method and can save on at least some control experiments. 
Such a kit according to the invention shall include at least the following components: 
A) compound of general formula (I) immobilized on a carrier material by 
30 covalent bonding 
B) at least one antibody, like detection antibody 
C) a standard solution 
The following components may also be included in such kits: 
35 D) blocking solution 
E) wash solution 
F) sample buffer 
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An antibody in the kit may be a specific antibody, which can be used as a capture 
antibody. But preferably it is at least an enzyme-linked secondary antibody used as 
detection antibody that binds specifically to antibody's Fe region. For quantitative 
determinations, the optical density (OD) or fluorescence of the sample is compared 
5 to a standard curve, which is typically a serial dilution of a known-concentration 
solution of the target molecule (a standard solution). A blocking solution may be a 
solution of a non-reacting protein, such as bovine serum albumin or casein, which is 
added to block any plastic surface in the well that remains uncoated by the antigen. 
Washing solutions are used to remove unbound components. A sample buffer may 
10 be used to dilute the sample of the patient (blood, serum, urine) so that the 
concentration of the target molecule is in the range which can normally be detected 
by the test system used. 
If the kit shall be allow for the immobilization of a compound of general formula (I) on 
15 a solid carrier material the kit should include at least: 
A) A compound of general formula (I) 
B) A carrier material, like a microtiter plate 
Thereby the carrier material may be modified, for example the carrier material may 
20 be modified with a functional group as described above. 
The following components may also be included in such kits: 
C) blocking solution 
D) wash solution 
25 E) reaction buffer 
30 
Description of the Figures 
Figure 1: Reaction scheme for the preparation of glycans 3, 4 and 5 as examples for 
a phosphate linked GPI. 
Figure 2: Reaction scheme for the preparation of glycan 22 as example for a sulfone 
35 linked GPI. 
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Figure 3: left side: Analysis of pooled serum that was obtained 4 weeks after 1st 
immunization of Balb/c mice with a conjugate consisting of CRM197 
covalently linked to compound 3; 
right side: Printing pattern: all compounds were printed in a 3x3 pattern 
and in a concentration of 1 mM; left, upper corner: compound 5; left lower 
corner: compound 3; right, upper corner: compound 4; right lower corner: 
(a-0-Mannopyranosyl)-(1 ~2)-(a-O-mannopyranosyl)-(1 ~2)-(a-0-
mannopyranosyl)-(1 ~6)-( a-O-mannopyranosyl)-(1 ~4 )-(2-amino-2-deoxy-
a-0-glucopyranosyl)-(1 ~6)-1-0-(6-thiohexyl phosphono)-0-myo-inositol 
(Chern. Eur. J. 2005, 11, 2493). From the fluorescence pattern it can be 
seen that such specific antibodies were produced by the mouse that these 
antibodies specifically evoke a binding to compound 3, and not to the 
structurally very related compounds 4, 5 and (a-0-Mannopyranosyl)-
(1 ~2)-(a-O-mannopyranosyl)-(1 ~2)-(a-O-mannopyranosyl)-(1 ~6)-(a-0-
mannopyranosyl)-(1 ~4 )-(2-amino-2-deoxy-a-O-glucopyranosyl)-(1 ~6)-1-
0-(6-th iohexyl phosphono )-0-myo-inositol. 
Figure 4: Fluorescence microscopic image of tachyzoiten stained with serum that 
was obtained after immunization of Balb/c mice with a conjugate consisting 
of compound 3 covalently linked to CRM197; blue: cell nucleus, DAPI; 
green: fluorescent secondary antibody. The fluorescence image shows that 
the mouse serum which was derived from a mouse immunized with a 
conjugate consisting of compound 3 covalently linked to CRM197 effectively 
binds to tachyzoites of T. gondii. 
Figure 5: A) Possible functional groups X being attached to a suitable carrier; B) 
Possible reaction pathway of attaching a compound of the general formula 
(I) to a carrier modified with a vinyl functional group X by an thiol-ene 
reaction upon activation by irradiation of light and/or by a radical starter. 
Figure 6: Preparation of conjugates of compounds 3 and 4 with CRM197 for 
immunization: a) maleimide-modification of CRM197 PBS, pH = 7.4, 
room temperature, 2 h b) coupling of compounds 3 and 4: PBS, pH = 
7.4, room temperature, 3 h. 
Figure 7: Selection of reactive bifunctional molecules A suitable for modifying a 
carrier material for subsequent introduction of a compound of the formula 
(I) on the carrier material by direct bonding. 
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Figure 8: Preparation of the conjugate of compound 4 with CRM197 for immunization: 
a) a-iodoacetamide modification of CRM197: PBS, pH = 7.4, 1 h, room 
temperature; b) coupling of compound 4: compound 4, PBS, pH = 8.5, 3 
h. 
Figure 9: MALDI-TOF analysis of A) CRM197 (blue, 58.5 kDa), B) CRM19r 
iodoacetamide (red, 68 kDa) and C) CRM19rGPI conjugate of compound 4 
with CRM197 (black, 72 kDa); D) Comparison of the MALDI-TOF analyses 
of CRM197 (blue, 58.5 kDa), CRM1griodoacetamide (red, 68 kDa) and 
CRM19rGPI conjugate of compound 4 with CRM197 (black, 72kDa). As a 
Matrix 2',4',6'- Trihydroxyacetophenone (THAP) was used. 
Figure 10: In flow preparation of the conjugate of compound 4 with a vinyl-modified 
glycosphingolipid with immunomodulatory properties. 
Figure 11: Serum antibody levels against compound 4 in mice immunized with the 
conjugate obtained as described in example 11 e: A) Total serum lgG 
levels; B) lgG subclass levels; Bars represent mean values averaged over 
all mice including standard error of the mean; Fl =fluorescence intensity. 
Figure 12: Specificity and epitope recognition of the antibody response: Pictures of 
microarrays incubated with serum (dilution 1 : 1 000) of the three mice six 
weeks after 1st immunization and a secondary fluorescent antibody 
directed against mouse lgG. Compound 4 as well as the shown 
substructures were printed at 1 001-JM. 
Figure 13: Recognition of the natural GPI antigen displayed on the T. gondii parasite 
by the antibodies raised against compound 4: IF pictures of 
paraformaldehyde-fixed purified T. gondii tachyzoites grown in human 
foreskin fibroblasts stained with (A) DAPI (B) pooled serum from 
immunized mice and a secondary FITC-conjugated anti-mouse-lgG (C) 
differential interference contrast picture and (D) merge of (A), (B) and (C). 
Full circle in (C) indicates the apical and half circle the basolateral end of 
the parasite (white bar= 5 1-1m). 
5 
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Experimental Part 
Part A1 : Preparation of phosphate linked thiol functionalized GPI 
Example 1: Triethylammonium 2,3,4-Tri-0-benzyl-6-0-triisopropylsilyl-a-D-
mannopyranosyl-(1 ~2)-3,4,6-tri-0-benzyl-a-D-mannopyranosyl-(1 ~6)-4-0-
(3,4,6-tri-O-benzyl-2-deoxy-2-acetamido-J3-D-galactopyranosyi)-3-0-benzyi-2-0-
levulinyl-a-D-mannopyranosyl-(1~4)-2-azido-3,6-di-0-benzyl-2-deoxy-a-D-
1 0 g lucopyranosyl-(1 ~6)-1-0-(6-( S-benzyl)thiohexyl phosphono )-2,3,4,5-tetra-0-
benzyi-D-myo-inositol (compound 12) 
TIPS~OBn 
BnO O 
BnO 
Bn~O BnO O 
BnO 
BnO~O O 
~~n ~O Olev 
NH BnO ~~n 
'r B~O~ BnO OBn 
N 3 o~l~oBn O~OBn 
BnS~o-p-oE> 
11 HNEt3 
0 0 
2,3,4-Tri-0-benzyl-6-0-triisopropylsilyl-a-D-mannopyranosyl-(1 ~2)-3,4,6-tri-0-
15 benzyl-a-D-mannopyranosyl-(1 ~6)-4-0-(3,4,6-tri-0-benzyl-2-deoxy-2-acetamido-13-
D-galactopyranosyl)-3-0-benzyi-2-0-Ievulinyl-a-D-mannopyranosyl-(1 ~4 )-2-azido-
3,6-di-0-benzyl-2-deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-allyl-2,3,4,5-tetra-0-benzyi­
D-myo-inositol (compound 9) (20mg, 7.261Jmol, 1 equiv) and triethylammonium 6-
(benzylthio)hexyl phosphonate (compound 10) (12.7mg, 331Jmol, 4.5equiv) are co-
20 evaporated 3 times with 2ml dry pyridine. The residue is dissolved in 2ml dry 
pyridine and PivCI (6.701JL, 541Jmol, 7.5equiv) is added. The solution is stirred for 2h 
at r.t. before water (1 OiJL, 0.56mmol, 76equiv) and iodine (1 0.1 mg, 401Jmol, 5.5 
equiv) are added. The red solution is stirred for 1 h and is quenched with sat. 
Na2S303. The reaction mixture is diluted with 1 Oml CHCI3 and dried over Na2S04. 
25 The solvents are removed in vacuo and the residue is purified through flash column 
chromatography (starting from CHCI3/MeOH 0%->5% MeOH) to yield yellow oil 
(18mg, 5.91Jmol, 82%). 
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[a]o20 = + 32.6 (c =1.00 in CHCb); Vmax (neat) 2926, 2864, 2107, 1742, 1720, 1677, 
1454, 1098, 1059, 1028cm-1; 1H NMR (600 MHz, CDCb) o 7.35 (d, J = 7.4 Hz, 2H), 
7.31 - 7.04 (m, 81 H), 6.99 (dd, J = 6.6, 2.8 Hz, 2H), 5.94 (d, J = 8.8 Hz, 1 H, NH), 
5.86 (d, J = 3.7 Hz, 1 H, GlcNH2-1 ), 5.27- 5.24 (m, 2H, Manl-2), 5.09 (d, J = 1.2 Hz, 
5 1 H), 4.96 (d, J = 12.0 Hz, 1 H, CH2 of Bn), 4.92- 4.81 (m, 3H, CH2 of Bn), 4.81 - 4.57 
(m, 11 H), 4.57- 4.48 (m, 4H), 4.48- 4.38 (m, 4H), 4.38- 4.19 (m, 12H), 4.11 - 3.72 
(m, 17H), 3.69 (dd, J = 9.7, 7.0 Hz, 1 H), 3.63- 3.54 (m, 8H), 3.52 (t, J = 6.4 Hz, 1 H), 
3.50 - 3.30 (m, 8H), 3.25 (dd, J = 7.8, 3.9 Hz, 2H), 3.05 (dd, J = 1 0.2, 3.7 Hz, 1 H, 
GlcNH2-2), 2.86 (q, J = 7.3 Hz, 6H, NCH2CH3), 2.28 (t, 2H, -S-CH2-CH2-CH2-CH2-
1 0 CH2-CH2-0 ), 2.23 - 2.08 (m, 4H, CH2 of Lev), 1.83 (s, 3H, NHAc), 1.56 - 1.48 (m, 
5H, CH3 of Lev, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.42 (mcentered, 2H, -S-CH2-CH2-
CH2-CH2-CH2-CH2-0), 1.26 - 1.14 (m, 13H, NCH2CH3, -S-CH2-CH2-CH2-CH2-CH2-
CH2-0), 1.00- 0.93 (m, 21 H, TIPS); 13C NMR (151 MHz, CDCb) o 205.92 (ketone of 
Lev), 171.77 (CO of Lev), 170.35 (CONH), 140.05, 139.05, 138.95, 138.88, 138.83, 
15 138.75, 138.68, 138.58, 138.57, 138.40, 138.33, 138.24, 138.05, 137.99, 137.71' 
128.92, 128.64, 128.62, 128.59, 128.57, 128.54, 128.46, 128.42, 128.40, 128.36, 
128.32, 128.28, 128.26, 128.21, 128.14, 128.11, 128.09, 128.08, 128.00, 127.96, 
127.84, 127.77, 127.72, 127.68, 127.67, 127.61' 127.56, 127.51' 127.49, 127.44, 
127.28, 127.14, 126.97, 126.94, 100.58, 99.48, 98.79, 98.66, 96.51 (GicNH2-1 ), 
20 81.99, 81.75, 81.23, 80.89, 80.52, 79.77, 79.24, 76.01' 75.76, 75.73, 75.57, 75.44, 
75.34, 75.13, 74.76, 74.57, 74.40, 74.37, 74.26, 74.24, 74.20, 73.93, 73.85, 73.62, 
73.27, 73.15, 72.96, 72.68, 72.40, 72.37, 72.32, 72.28, 72.09, 71.57, 71.49, 71.07, 
70.77, 69.95 (Manl-2), 69.76, 68.98, 68.74, 66.74, 65.73, 65.69, 63.71 (GicNH2-2), 
62.94, 53.25, 45.58, 37.90, 36.38, 31.46, 31.07, 31.02, 29.69, 29.30, 28.82, 28.06, 
25 25.55, 23.22, 18.24, 18.18, 12.17, 8.74; 31 P NMR (162 MHz, CDCI3) o -0.30; m/z 
(ESI) Found: [M+Nar, 3062.3573 C177H2o5N4035PSSi requires [M+Nar, 3062.3577. 
Example 2: Triethylammonium 2,3,4-Tri-0-benzyl-a-D-mannopyranosyl-(1 ~2)-
30 3,4,6-tri-O-benzyl-a-D-mannopyranosyi-(1~6)-4-0-(3,4,6-tri-O-benzyl-2-deoxy-2-
acetamido-J3-D-galactopyranosyi)-3-0-benzyi-2-0-Ievulinyl-a-D-
mannopyranosyl-(1~4)-2-azido-3,6-di-0-benzyl-2-deoxy-a-D-glucopyranosyl-
(1 ~6)-1-0-(6-( S-benzyl)thiohexyl phosphono )-2,3,4,5-tetra-0-benzyi-D-myo-
inositol (compound 18) 
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T riethylam mon ium 2,3 ,4-T ri-0-benzyl-6-0-triisopropyls ilyl-a-0-man nopyranosyl-
( 1 ~2 )-3 ,4 ,6-tri-0-benzyl-a-D-man nopyranosyl-( 1 ~6 )-4-0-(3,4 ,6-tri-0-benzyl-2-
deoxy-2-acetam ido-13-D-galactopyranosyl )-3-0-benzyl-2-0-levu I inyl-a-D-
5 mannopyranosyl-(1 ~4 )-2-azido-3,6-di-0-benzyl-2-deoxy-a-D-glucopyranosyl-(1 ~6)-
1-0-(6-( S-benzyl )th iohexyl phosphono )-2,3,4 ,5-tetra-0-benzyi-D-myo-inositol 
(compound 12) (59mg, 191Jmol, 1 equiv) is dissolved in 2mL MeCN. Water (13.51JL, 
0.75mmol, 40equiv) and Sc(Tf0)3 (18.5mg, 381Jmol, 2equ.) are added and the 
solution is heated up to 50°C for 5h. The reaction is quenched with pyridine (7.61JL, 
10 941Jmol, 5 equiv) and the solvents are removed in vacuo. The residue is purified 
through flash column chromatography (starting from CHCI3/MeOH 0%->5% MeOH) 
to yield colorless oil (52mg, 181Jmol, 93%). 
[a]o20 = + 31.3 (c =1.10 in CHCb); Vmax (neat) 3346, 2925, 2107, 1742, 1719, 1669, 
1497, 1454, 1362, 1048, 912cm-1; 1H NMR (600 MHz, CDCI3) o 7.43-6.88 (m, 85H), 
15 6.01 (d, J = 8.2 Hz, 1 H, NH), 5.88 (d, J = 3.7 Hz, 1 H, GlcNH2-1 ), 5.27- 5.14 (m, 2H, 
Manl-2), 4.94 (m, 1 H), 4.90 - 4.63 (m, 13H), 4.59 (d, J = 10.7 Hz, 1 H), 4.55- 4.28 
(m, 18H), 4.25- 4.20 (m, 1 H), 4.17 (dd, J = 11.8, 5.3 Hz, 2H), 4.13- 3.97 (m, 3H), 
3.95 (t, J = 2.2Hz, 1 H), 3.90 (t, J = 9.6Hz, 1 H), 3.87- 3.50 (m, 23H), 3.49- 3.38 (m, 
?H), 3.16 (dd, J = 6.9, 3.1 Hz, 1 H), 3.06 (dd, J = 1 0.2, 3.7 Hz, 1 H, GlcNH2-2), 2.76 (q, 
20 J = 7.2 Hz, 6H, NCH2CH3), 2.34 - 2.08 (m, 6H, CH2 of Lev, -S-CH2-CH2-CH2-CH2-
CH2-CH2-0), 1.85 (s, 3H, CH3 of Lev), 1.64 (s, 3H, NHAc), 1.54 - 1.47 (m, 2H, -S-
CH2-CH2-CH2-CH2-CH2-CH2-0), 1.45- 1.37 (m, 2H, -S-CH2-CH2-CH2-CH2-CH2-CH2-
0), 1.25 - 1.16 (m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.13 (t, J = 7.3 Hz, 9H, 
NCH2CH3); 13C NMR (151 MHz, CDCb) o 206.17 (ketone of Lev), 171.72, 170.70, 
25 140.03, 139.03, 138.87, 138.74, 138.69, 138.65, 138.62, 138.52, 138.48, 138.44, 
138.41, 138.35, 138.19, 138.10, 138.00, 128.91, 128.63, 128.54, 128.53, 128.47, 
128.45, 128.39, 128.36, 128.34, 128.33, 128.30, 128.28, 128.25, 128.11' 128.09, 
128.08, 128.02, 128.00, 127.96, 127.81' 127.81' 127.77, 127.73, 127.67, 127.60, 
127.56, 127.52, 127.47, 127.45, 127.43, 127.34, 127.24, 127.12, 126.93, 100.75, 
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99.86, 99.32, 98.90, 96.39 (GicNH2-1 ), 81.92, 81.79, 81.18, 80.09, 80.05, 79.55, 
79.07, 76.08, 75.92, 75.72, 75.41, 75.26, 75.14, 75.10, 75.05, 74.94, 74.73, 74.55, 
74.10, 73.95, 73.52, 73.48, 73.43, 73.09, 73.03, 72.42, 72.36, 72.29, 72.23, 72.18, 
71.72, 71.28, 69.97, 69.67, 69.46 (Manl-2), 68.90, 68.67, 67.15, 65.71, 65.67, 63.39 
5 (Gic-NH2-2), 62.37, 54.27, 45.89 (NCH2CH3), 37.88, 36.36, 31.45 (-S-CH2-CH2-CH2-
CH2-CH2-CH2-0), 31.06, 31.01, 29.70, 29.29, 28.81, 28.01, 25.54, 23.44, 9.62 
(NCH2CH3); 31 P NMR (243 MHz, CDCI3) o -1.08; m/z (ESI) Found: [M+Nar, 
2922.2032 C16sH1ssN403sPSSi requires [M+Nar, 2922.1969. 
10 Example 3: Bistriethylammonium 2,3,4-Tri-0-benzyi-6-0-(2-(N-benzyloxy 
carbonyl) aminoethyl phosphono)-a-D-mannopyranosyl-(1-2)-3,4,6-tri-O-
benzyl-a-D-mannopyranosyi-(1-6)-4-0-(3,4,6-tri-O-benzyl-2-deoxy-2-
acetamido-(3-D-galactopyranosyl)-3-0-benzyl-a-D-mannopyranosyl-(1-4)-2-
azido-3,6-d i-0-benzyl-2-deoxy-a-D-g lucopyranosyl-( 1-6)-1-0-(6-( S-
15 benzyl)thiohexyl phosphono)-2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 
15) 
Triethylammonium 2,3,4-Tri-0-benzyl-a-D-mannopyranosyl-(1-2)-3,4,6-tri-0-benzyl-
a-D-man nopyranosyl-( 1-6 )-4-0-(3,4 ,6-tri-0-benzyl-2-deoxy-2-acetam ido-13-D-
20 galactopyranosyl)-3-0-benzyl-2-0-levulinyl-a-D-mannopyranosyl-(1-4 )-2-azido-3,6-
di-0-benzyl-2-deoxy-a-D-glucopyranosyi-(1-6)-1-0-(6-(S-benzyl)thiohexyl 
phosphono)-2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 18) (28.3mg, 781..Jmol, 
4.5equiv) and triethylammonium 2-(((benzyloxy)carbonyl)amino)ethyl phosphonate 
(compound 13) (28.3mg, 781..Jmol, 4.5equiv) are co evaporated 3 times with 2ml dry 
25 pyridine. The residue is dissolved in 2ml dry pyridine and PivCI (16.11..JL, 1311..Jmol, 
7.5equiv) is added. The solution is stirred for 2h at r.t. before water (15.61..JL, 
0.87mmol, 50equiv) and iodine (24.3 mg, 961..Jmol, 5.5 equiv) are added. The red 
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solution is stirred for 1 h and is quenched with hydrazine (1M in THF; 3001-JL, 
0.3mmol, 17equiv).The reaction mixture is stirred for 18h. The solvents are removed 
in vacuo and the residue is purified through flash column chromatography (starting 
from CHCI3/MeOH: 97/3-790/1 0) to yield yellow oil (49.5mg, 151-Jmol, 88%). 
5 [a]o20 = + 32.5 (c =1.00 in CHCI3); Vmax (neat) 3387, 3063, 2929, 2108, 1672, 1497, 
1057, 1029, 839cm-1; 1H NMR (400 MHz, CDCb) o 7.37-6.90 (m, 90H), 6.28 (s, 1 H, 
NHAc), 5.89 (d, J = 3.5 Hz, 1 H, GlcNH2-1 ), 5.19 (d, J = 1.6 Hz, 1 H), 5.05- 4.15 (m, 
40H), 4.14-4.02 (m, 3H), 3.98-3.35 (m, 36H), 3.28-3.20 (m, 1 H), 3.14 (dd, J = 
9.2, 4.5 Hz, 1 H), 3.05 (dd, J = 1 0.2, 3.5 Hz, 1 H, GlcNH2-2), 2.61 (q, J = 7.3 Hz, 12H, 
10 NCH2CH3), 2.28 (t, J = 7.4 Hz , 2H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.92 - 1.76 
(m, 3H, COCH3), 1.58- 1.37 (m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.26- 1.13 
(m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 0.97 (t, J = 7.3 Hz, 18H, NCH2CH3); 13C 
NMR (151 MHz, CDCb) o 170.84 (COCH3), 156.58 (O(CO)NH), 138.71, 128.87, 
128.50, 128.44, 128.36, 128.30, 128.21' 128.03, 127.94, 127.86, 127.76, 127.50, 
15 126.91, 102.05, 101.15, 100.26, 98.71, 96.19, 82.02, 81.79, 81.06, 80.17, 80.03, 
79.66, 77.37, 77.16, 76.95, 76.36, 75.93, 75.58, 75.19, 74.84, 74.80, 74.65, 74.03, 
73.49, 72.79, 72.29, 71.62, 71.56, 71.49, 71.41' 70.08, 69.75, 69.64, 68.97, 66.34, 
65.70, 65.04, 64.09, 63.49, 58.17, 45.70, 38.76, 36.34, 32.00, 31.44, 29.78, 29.59, 
29.44, 29.27, 28.80, 27.54, 25.50, 22.77, 14.21, 8.71; 31 P NMR (243 MHz, CDCb) o-
20 0.03, -1.67; m/z (ESI) Found: [M-Hr, 3041.2393 C173H191Ns03sP2S requires [M-Hr, 
3041.2353. 
Example 4: 6-0-(aminoethyl phosphono)-a-D-mannopyranosyl-(1~2)-a-D­
man nopyranosyl-( 1 ~6) -4-0-(2-d eoxy-2 -ace tam ido-J3-D-ga lactopyranosyl) -a-D-
25 mannopyranosyl-(1 ~4)-2-amino-2-deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-
(thiohexyl phosphono)-D-myo-inositol (compound 3) 
0 H2N~ II 
0-,P-O~H 
HO HO 0 
HO 
H~O HO O 
HO 
HO~OJt; 
NH HO ~H y 0 0 
o HO HO OH 
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Approximately 10 ml ammonia were condensed in a flask and terl-BuOH (2 drops) 
was added. Afterwards small pieces of sodium were added till a dark blue colour was 
established. Bistriethylammonium 2,3,4-Tri-0-benzyi-6-0-(2-(N-benzyloxycarbonyl) 
aminoethyl phosphono )-a-0-mannopyranosyl-(1 ~2)-3,4,6-tri-0-benzyl-a-0-
5 mannopyranosyl-(1 ~6)-4-0-(3,4,6-tri-0-benzyl-2-deoxy-2-acetamido-~-0-
galactopyranosyl)-3-0-benzyl-a-0-mannopyranosyl-(1 ~4 )-2-azido-3,6-di-0-benzyl-
2-deoxy-a-0-glucopyranosyl-(1 ~6)-1-0-(6-( S-benzyl)thiohexyl phosphono )-2,3,4,5-
tetra-0-benzyl-0-myo-inositol (compound 15) (28 mg, 8.6 1-Jmol) was dissolved in 
dry THF (1.5 ml) and added to the ammonium solution at -78 °C. The reaction was 
10 stirred for 30 min at this temperature. The reaction was quenched with dry MeOH (2 
ml) and the ammonia was blown off using a stream of nitrogen. The pH of the 
resulting solution was adjusted with concentrated acetic acid to 8-9. Solvents were 
removed in vacuo and the residue was purified using a small G1 0 column (GE 
Healthcare) to yield X as white solid (6.7 mg, 4.9 1-Jmol, 58%): 1H NMR (600 MHz, 
15 020) o 5.54 (d, J = 3.9 Hz, 1 H, GlcNH2), 5.23 (s, 1 H), 5.19 (s, 1 H), 5.03 (s, 1 H), 4.51 
(d, J = 8.3 Hz, 1 H, GaiNAc-1 ), 4.29- 3.66 (m, 36H), 3.63- 3.53 (m, 2H), 3.45 (td, J 
= 9.3, 4.3 Hz, 1 H), 3.38 (dd, J = 1 0.9, 4.3 Hz, 1 H, GlcNH2-2), 3.34 - 3.29 (m, 2H), 
2.80 (t, J = 7.1 Hz, 1 H), 2.58 (t, J = 7.1 Hz, 1 H), 2.12 (s, 3H, Me of NHAc), 1.80 -
1.59 (m, 4H, linker), 1.51 - 1.36 (m, 4H, linker); 13C NMR (151 MHz, 020) o 177.30 
20 (amide), 105.02, 104.34 (GaiNAc-1 ), 104.09, 101.16, 98.15 (Gic-NH2-1 ), 81.69, 
79.37, 78.78, 78.01' 75.69, 75.40, 74.84, 74.60, 74.05, 73.92, 73.62, 73.15, 73.08, 
72.82, 72.64, 72.49, 72.03, 71.56, 70.32, 69.61' 69.21' 68.85, 67.28, 64.53, 64.50, 
63.76, 63.70, 62.81, 56.64 (GicNH2-2), 55.19, 42.66, 40.73, 35.53, 32.31, 30.88, 
29.67, 27.20, 27.00, 26.29, 24.96 (Me of NHAc); 31 P NMR (243 MHz, 020) o -2.62, -
25 2.83; m/z (ESI) Found: [M-2Ht, 673.7104 C45HssN3036P2S requires [M-2Ht, 
673.6981. 
Example 5: Tristriethylammonium 2,3,4-Tri-0-benzyi-6-0-(2-(N-
30 benzyloxycarbonyl) aminoethyl phosphono)-a-D-mannopyranosyl-(1 ~2)-3,4,6-
tri-0-benzyl-a-D-mannopyranosyl-(1 ~6)-4-0-(3,4,6-tri-O-benzyl-2-deoxy-2-
acetamido-J3-D-galactopyranosyi)-2-(2-(N-benzyloxycarbonyl) aminoethyl 
phosphono )-3-0-benzyl-a-D-mannopyranosyl-( 1 ~4 )-2-azido-3,6-d i-0-benzyl-2-
deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-(6-( S-benzyl)thiohexyl phosphono)-
35 2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 16) 
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Bistriethylammonium 2,3,4-Tri-0-benzyi-6-0-(2-(N-benzyloxycarbonyl) aminoethyl 
phosphono )-a-D-man nopyranosyl-( 1 ~2)-3,4 ,6-tri-0-benzyl-a-D-man nopyranosyl-
( 1 ~6 )-4-0-(3,4 ,6-tri-0-benzyl-2-deoxy-2-acetam ido-13-D-galactopyranosyl )-3-0-
5 benzyl-a-D-mannopyranosyl-(1 ~4 )-2-azido-3,6-di-0-benzyl-2-deoxy-a-D-
glucopyranosyl-(1 ~6)-1-0-(6-(S-benzyl)thiohexyl phosphono)-2,3,4,5-tetra-0-
benzyi-D-myo-inositol (compound 15) (15mg, 4.61Jmol, 1equiv) and 
triethylammonium 2-( ((benzyloxy)carbonyl)amino )ethyl phosphonate (compound 13) 
(8.1 mg, 22.51Jmol, 4.5equiv) are co evaporated 3 times with 2ml dry pyridine. The 
10 residue is dissolved in 2ml dry pyridine and PivCI (4.61JL, 36.81Jmol, 7.5equiv) is 
added. The solution is stirred for 2h at r.t. before water (1 OiJL, 0.56mmol, 76equiv) 
and iodine (6.8, 271Jmol, 5.5 equiv) are added. The red solution is stirred for 1 h and is 
quenched with sat. Na2S303. The reaction mixture is diluted with 1 Oml CHCI3 and 
dried over Na2S04. The solvents are removed in vacuo and the residue is purified 
15 through flash column chromatography (CHCI3/MeOH 1 00/0-780/20) to yield yellow 
oil (13.5mg, 3.81Jmol, 76%). 
[a]o20 = + 22.0 (c =1.00 in CHCb); Vmax (neat) 3358, 2927, 2108, 1641, 1454, 1398, 
1054, 7028, 838, 804cm-1; 1H NMR (600 MHz, CDCb) o 7.56- 6.77 (m, 90H), 6.44 
(s, 2H, CbzNH), 6.22 (s, 1 H, NHCOCH3), 5.87 (s, 1 H, GlcNH2-1 ), 5.49 (s, 1 H), 5.09-
20 3.35 (m, 83H), 3.30 (dd, J = 14.2, 7.1 Hz, 1 H), 3.26 - 3.17 (m, 2H), 3.17- 3.08 (m, 
2H), 3.07- 2.79 (m, 1 H), 2.58 (q, J = 7.2 Hz, 18H, NCH2CH3), 2.27 (t, J = 7.4Hz, 2H, 
-S-CH2-CH2-CH2-CH2-CH2-CH2-0), 2.05 - 1.98 (m, 2H), 1.90 - 1.83 (m, 3H, 
NHCOCH3), 1.59- 1.36 (m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.27- 1.12 (m, 
4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 0.99 (t, J = 7.2 Hz, 27H, NCH2CH3); 13C 
25 NMR (151 MHz, CDCI3) o 156.57 (OCONH), 140.07, 139.03, 138.78, 138.73, 138.67, 
138.32, 137.23, 128.93, 128.54, 128.49, 128.44, 128.39, 128.36, 128.31' 128.28, 
128.25, 128.23, 128.18, 128.03, 128.01' 127.97, 127.93, 127.82, 127.71' 127.60, 
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127.57, 127.54, 127.51, 127.41, 127.38, 127.30, 127.15, 127.06, 126.94, 126.84, 
100.59, 98.53, 96.54 (GicNH2-1 ), 81.89, 81.20, 75.58, 75.04, 74.83, 74.67, 73.28, 
72.84, 72.30, 66.39, 66.23, 65.70, 63.97, 45.85 (NCH2CH3), 42.97, 42.52, 40.1 0, 
36.39, 34.58, 33.94, 32.05, 31.56, 31.50 (S-CH2-CH2-CH2-CH2-CH2-CH2-0), 31.08, 
5 31.03, 30.33, 29.82, 29.79, 29.74, 29.63, 29.48, 29.32, 29.28, 29.08, 28.84, 25.55, 
22.81, 21.56, 14.99, 14.30, 14.24, 13.23, 9.91 (NCH2CH3); 31 P NMR (243 MHz, 
CDCI3) o 0.17, -0.02, -1.15; m/z (ESI) Found: [M+5Na-3H]2+, 1705.6285 
C1s3H2o3N5043P3S requires [M+5Na-3H]2+, 1705.6062. 
10 Example 6: 6-0-(aminoethyl phosphono)-a-D-mannopyranosyl-(1 ~2)-a-D-
15 
man nopyranosyl-( 1 ~6)-2-0--( am inoethyl phosphono )-4-0-(2-deoxy-2-
acetamido-J3-D-galactopyranosyl)-a-D-mannopyranosyl-(1~4)-2-amino-2-
deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-(thiohexyl phosphono)-D-myo-inositol 
(compound 5) 
Tristriethylammonium 2,3,4-Tri-0-benzyi-6-0-(2-(N-benzyloxycarbonyl) aminoethyl 
phosphono )-a-D-man nopyranosyl-( 1 ~2)-3,4 ,6-tri-0-benzyl-a-D-man nopyranosyl-
20 ( 1 ~6 )-4-0-(3,4 ,6-tri-0-benzyl-2-deoxy-2-acetam ido-13-D-galactopyranosyl )-2-(2-( N-
benzyloxycarbonyl) aminoethyl phosphono )-3-0-benzyl-a-D-mannopyranosyl-(1 ~4 )-
2-azido-3,6-di-0-benzyl-2-deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-(6-(S-
benzyl )th iohexyl phosphono )-2,3,4 ,5-tetra-0-benzyi-D-myo-inositol (compound 16) 
(22mg, 6.11-Jmol, 1 equiv) was dissolved in dry THF (15ml) and dry terl-BuOH 
25 (0.1 ml). The solution is cooled down to -78oC and approximately 20ml ammonia is 
condensed in the flask. Afterwards small pieces of sodium are added. The solution is 
wo 2014/016317 PCT/EP2013/065559 
42 
warmed to about -4ooc till a dark blue colour is established. Then the solution is 
cooled down to -78oC and the reaction is stirred for 1 h at this temperature. The 
reaction is quenched with 2ml dry MeOH and the ammonia is blown off of using a 
stream of nitrogen. Solvents are afterwards evaporated and the residue is dissolved 
5 in 5ml water. The pH of the solution is adjusted with concentrated acetic acid to 4-7. 
Water is removed by freeze drying and the residue is purified using a small G25 
column (1cmx20cm) to yield a white solid (2.6 mg, 1.81-Jmol, 29%). 
1H NMR (400 MHz, D20) o 5.57-5.52 (m, 1 H, GlcNH2-1 ), 5.45 (s, 1 H, Manl-1 ), 5.19 
(s, 1 H), 5.04 (s, 1 H), 4.53 (d, J = 8.4 Hz, 2H, GaiNAc-1, Manl-2), 4.29 - 3.64 (m, 
10 37H), 3.62 - 3.53 (m, 2H), 3.44 (t, J = 9.3 Hz, 1 H), 3.41 - 3.34 (m, 1 H), 3.34 - 3.26 
(m, 4H), 2.79 (t, J = 7.3 Hz, 2H, HS-CH2), 2.11 (s, 3H, Me of NHAc), 1.81 - 1.57 (m, 
4H), 1.53 - 1.36 (m, 4H).; 31 P NMR (162 MHz, 0 20) o 0.36, 0.14, -0.81; m/z (ESI) 
Found: [M-3Hr3, 979.96 Cg6H1soNs0ysP6S2 requires [M-3Hr3, 979.93. 
15 Example 7: Triethylammonium 2,3,4-Tri-0-benzyl-6-0-triisopropylsilyl-a-D-
mannopyranosyl-(1 ~2)-3,4,6-tri-0-benzyl-a-D- mannopyranosyl-(1 ~6)-3-0-
benzyl-4-0-(2,3,4,6-tetra-0-benzyl-a-D-glucopyranosyl-(1 ~4)-3,6-di-O-benzyl-2-
deoxy-2-acetamido-J3-D-galactopyranosyi)-2-0-Ievulinyl-a-D-manno-pyranosyl-
( 1 ~4)-2-azido-3,6-d i-0-benzyl-2-deoxy-a-D-glucopyranosyl-( 1 ~6)-1-0-(6-( S-
20 benzyl)thiohexyl phosphono)-2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 
11) 
TIPS~OBn 
BnO 0 
BnO 
Bno~Q BnO o BnO Bn~O BnO~ BnO 
BnO~gn ~O OLev 
BnO~O O 
NH BnO ~g'n 
"! B~O~ BnO OBn 
11 N3o~l~osn ~0-P-O~OBn 
BnS 0
1 U\ e -±-
HNEt3 
2,3,4-Tri-0-benzyl-6-0-triisopropylsilyl-a-D-mannopyranosyl-(1 ~2)-3,4,6-tri-0-
25 benzyl-a-D- mannopyranosyl-(1 ~6)-3-0-benzyl-4-0-(2,3,4,6-tetra-0-benzyl-a-D­
glucopyranosyl-(1 ~4 )-3,6-di-0-benzyl-2-deoxy-2-acetamido-~-D-galactopyranosyl)-
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2-0-levulinyl-a-D-manno-pyranosyi-(1----A )-2-azido-3,6-di-0-benzyl-2-deoxy-a-D-
glucopyranosyl-(1 ~6)-2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 8) (50mg, 
161Jmol, 1 equiv) and triethylammonium 6-(benzylthio)hexyl phosphonate (compound 
10) (39mg, 1001Jmol, 6.4equ.) are co evaporated 3 times with 2mL dry pyridine. The 
5 residue is dissolved in 2mL dry pyridine and PivCI (14.51JL, 1181Jmol, 7.5equiv) is 
added. The solution is stirred for 2h at r.t. before water (141JL, 0.79mmol, 50equiv) 
and iodine (29.9mg, 1181Jmol, 7.5 equiv) are added. The red solution is stirred for 1 h 
and is quenched with sat. Na2S303. The reaction mixture is diluted with 1 OmL CHCI3 
and dried over Na2S04. The solvents are removed in vacuo and the residue is 
1 0 purified through flash column chromatography (CHCb/MeOH 1 00/0-795/5) to yield 
yellow oil (49mg, 141Jmol, 87%). 
[a]o20 = + 42.3 (c =1.00 in CHCb); Vmax (neat) 3064, 3032, 2926, 2865, 2107, 1742, 
1720, 1678, 1497, 1454, 1362, 1054, 1028, 913cm-1; 1H NMR (600 MHz, CDCb) o 
7.49- 6.87 (m, 1 OOH), 6.07 (d, J = 9.0 Hz, 1 H, NH), 5.78 (s, 1 H), 5.25 (s, 2H, Manl-
15 2), 5.07 (s, 1 H), 4.94 (d, J = 11.9 Hz, 1 H, CH2 of Bn), 4.89 - 3.89 (m, 49H), 3.86 -
3.74 (m, 11 H), 3.73- 3.66 (m, 2H), 3.63 (dd, J = 8.9, 2.9 Hz, 1 H), 3.60- 3.45 (m, 
11 H), 3.44- 3.36 (m, 4H), 3.34- 3.22 (m, 5H), 3.03 (dd, J = 10.1, 3.6 Hz, 1 H), 2.85 
(q, J = 7.3 Hz, 6H, NCH2CH3), 2.78 (d, J = 9.4 Hz, 1 H), 2.27 (t, J = 7.4 Hz, 2H, BnS-
CH2), 2.24 - 2.04 (m, 4H, CH2 of Lev), 1.80 (s, 3H, CH3 of Lev), 1.70 (s, 3H, 
20 NHCOCH3), 1.55- 1.34 (m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.23- 1.16 (m, 
4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.12 (t, J = 7.6 Hz, 9H, NCH2CH3), 1.00 -
0.94 (m, 21 H, TIPS); 13C NMR (151 MHz, CDCb) o 205.92 (ketone of Lev), 171.76 
(CO of Lev), 170.21 (NHCOCH3), 140.02, 139.09, 139.03, 138.94, 138.91, 138.84, 
138.76, 138.74, 138.69, 138.60, 138.57, 138.30, 138.15, 138.10, 138.01, 137.54, 
25 128.92, 128.77, 128.72, 128.65, 128.62, 128.57, 128.54, 128.46, 128.44, 128.39, 
128.36, 128.33, 128.31' 128.28, 128.27, 128.25, 128.24, 128.22, 128.16, 128.12, 
128.10, 128.07, 127.98, 127.87, 127.84, 127.82, 127.77, 127.71' 127.67, 127.65, 
127.63, 127.57, 127.55, 127.52, 127.48, 127.44, 127.29, 127.27, 127.18, 127.14, 
126.94, 126.45, 101.71' 100.84, 99.65, 98.84, 98.65, 96.71' 82.20, 81.99, 81.51' 
30 81.19, 81.03, 80.51' 80.12, 79.80, 79.13, 77.95, 77.53, 76.81' 75.93, 75.74, 75.43, 
75.35, 75.26, 75.15, 74.75, 74.69, 74.54, 74.43, 74.03, 73.86, 73.63, 73.48, 73.23, 
73.20, 73.00, 72.85, 72.39, 72.36, 72.07, 71.53, 71.37, 70.88, 70.79, 70.06 (Manl-2), 
69.67, 68.77, 68.59, 67.74, 66.87, 65.80, 63.72, 62.90, 52.87, 45.42 (NCH2CH3), 
38.57, 37.83, 36.38, 31.46, 31.00, 30.95, 29.82, 29.66, 29.30 (CH3 of Lev), 28.81, 
35 28.04, 27.69, 27.41, 25.52, 23.31 (NHCOCH3), 18.24, 18.18, 14.25, 12.18, 8.55 
(NCH2CH3); 31 P NMR (243 MHz, CDCI3) o -1.45; m/z (ESI) Found: [M-2Ht, 
1734.7564 C2o4H233N404oPSSi requires [M-2Ht, 1734.7730. 
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Example 8: Triethylammonium 2,3,4-Tri-0-benzyl-a-D-mannopyranosyl-(1 ~2)-
3,4,6-tri-0-benzyl-a-D- mannopyranosyl-(1 ~6)-3-0-benzyi-4-0-(2,3,4,6-tetra-O­
benzyl-a-D-glucopyranosyl-(1~4)-3,6-di-O-benzyl-2-deoxy-2-acetamido-J3-D­
galactopyranosyl)-2-0-levulinyl-a-D-manno-pyranosyl-(1~4)-2-azido-3,6-di-0-
5 benzyl-2-deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-(6-( S-benzyl)thiohexyl 
phosphono )-2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 17) 
H~OBn BnO O 
BnO 
BnO~q BnO 0 BnO Bn~O 
BnO~ BnO 
BnO~gn ~0 Olev 
BnO~O 0 
NH BnO ~g'n 
"8 B~O~ BnO OBn ~ N3o~l~osn ~0-P-O~OBn 
BnS 0
1 Q 8 1±1 
HNEt3 
Triethylam mon ium 2,3 ,4-Tri-0-benzyl-6-0-triisopropyls ilyl-a-0-man nopyranosyl-
(1 ~2)-3,4,6-tri-0-benzyl-a-D- mannopyranosyl-(1 ~6)-3-0-benzyl-4-0-(2,3,4,6-tetra-
1 0 0-benzyl-a-D-glucopyranosyl-(1 ~4 )-3,6-di-0-benzyl-2-deoxy-2-acetamido-~-D­
galactopyranosyl)-2-0-levulinyl-a-D-manno-pyranosyl-(1 ~4 )-2-azido-3,6-di-0-
benzyl-2-deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-(6-( S-benzyl)thiohexyl phosphono )-
2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 11) (43mg, 121-Jmol, 1 equiv) is 
dissolved in 2mL MeCN. Water (8.71-JL, 0.48mmol, 40equiv) and Sc(Tf0)3 (11.8mg, 
15 241-Jmol, 2equiv) are added and the solution is heated up to 50°C for 5h. The reaction 
is quenched with pyridine (4.81-JL, 601-Jmol, 5 equiv) and the solvents are removed in 
vacuo. The residue is purified through flash column chromatography (CHCb/MeOH 
1 00/0-795/5) to yield colorless oil (32mg, 9.41-Jmol, 78%). 
[a]o20 = + 47.4 (c =1.00 in CHCb); Vmax (neat) 3363, 3031, 2926, 2862, 2107, 1742, 
20 1719, 1671, 1497, 1454, 1362, 1068, 1049, 1028, 697cm-1; 1H NMR (600 MHz, 
CDCb) o 7.55- 6.71 (m, 1 OOH), 6.19 (s, 1 H, NH), 5.87 (s, 1 H), 5.20 (s, 1 H), 5.17 (s, 
1 H), 5.03 - 4.16 (m, 40H), 4.15 - 3.33 (m, 43H), 3.28 (d, J = 10.6 Hz, 1 H), 3.21 -
3.11 (m, 1 H), 3.02 (d, J = 7.7 Hz, 1 H), 2.87 (d, J = 10.1 Hz, 1 H), 2.80 (q, J = 7.0 Hz, 
6H, NCH2CH3), 2.35- 2.13 (m, 6H, BnS-CH2, CH2 of Lev), 1.85 (s, 3H, CH3 of Lev), 
25 1.75 (s, 3H, NHCOCH3), 1.59- 1.35 (m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.28 
- 1.13 (m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.10 (t, J = 7.3 Hz, 1 H, NCH2CH3); 
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13C NMR (151 MHz, CDCb) o 206.20 (ketone of Lev), 171.68 (CO of Lev), 170.78 
(NHCO), 149.97, 140.04, 139.04, 138.99, 138.87, 138.78, 138.68, 138.64, 138.54, 
138.49, 138.30, 138.20, 138.10, 128.93, 128.82, 128.55, 128.49, 128.48, 128.43, 
128.39, 128.37, 128.33, 128.30, 128.17, 128.08, 128.03, 127.96, 127.90, 127.80, 
5 127.75, 127.66, 127.62, 127.59, 127.55, 127.53, 127.45, 127.35, 127.12, 126.95, 
126.82, 101.45, 100.42, 100.04, 99.52, 99.19, 96.41, 82.15, 81.91, 81.21, 80.37, 
79.99, 79.65, 77.96, 76.20, 75.86, 75.70, 75.36, 75.29, 75.13, 75.04, 74.93, 74.74, 
74.1 0, 73.60, 73.53, 73.36, 73.29, 73.00, 72.56, 72.37, 72.31' 72.26, 72.17, 71.69, 
71.20, 70.79, 69.84, 69.48, 69.26 (Manl-2), 69.00 67.98, 67.79, 65.75, 65.71, 63.32, 
10 62.50, 54.82, 45.44 (NCH2CH3), 37.88, 36.39, 32.06, 31.47, 31.06, 29.91, 29.83, 
29.72, 29.45, 29.39, 29.31' 28.84, 28.03, 27.71' 27.36, 25.55, 23.59, 22.83, 17.85, 
14.26, 12.43, 8.60 (NCH2CH3); 31 P NMR (243 MHz, CDCb) o -1.12; m/z(ESI) Found: 
[M+CI-Ht, 1673.6842 C19sH213N404oPS requires [M+CI-Ht, 1673.6918. 
15 Example 9: Bistriethylammonium 2,3,4-Tri-0-benzyi-6-0-(2-(N-
benzyloxycarbonyl) aminoethyl phosphono)-a-D-mannopyranosyl-(1~2)-3,4,6-
tri-0-benzyl-a-D- mannopyranosyl-(1 ~6)-3-0-benzyl-4-0-(2,3,4,6-tetra-0-
benzyl-a -D -g I u copyranosyl-( 1 ~4) -3, 6-d i-0-benzyl-2 -d eoxy-2 -acetam id o-J3-D-
galactopyranosyl)-a-0-manno-pyranosyl-( 1 ~4 )-2-azido-3,6-d i-0-benzyl-2-
20 deoxy-a-D-glucopyranosyl-(1 ~6)-1-0-(6-( S-benzyl)thiohexyl 
2,3,4,5-tetra-0-benzyi-D-myo-inositol (compound 14) 
0 CbzHN~O-p 
HNEt3 , ----~oBn 
ffi O BnO 0 
8 BnO 
BnO~q BnO 0 BnO BnO~O BnO~ BnO 
BnO~gn ~0 OH 
BnO~O O 
NH BnO ~g,n 8 B~O~ BnO OBn 
11 N3o~l~osn ~0-P-O~OBn 
BnS 0
1 ~ 8 1±1 
HNEt3 
phosphono)-
Triethylammonium 2,3,4-Tri-0-benzyl-a-D-mannopyranosyl-(1 ~2)-3,4,6-tri-0-benzyl­
a-D- mannopyranosyl-(1 ~6)-3-0-benzyl-4-0-(2,3,4,6-tetra-0-benzyl-a-D-
25 glucopyranosyl-(1 ~4 )-3,6-di-0-benzyl-2-deoxy-2-acetamido-13-D-galactopyranosyl)-
2-0-levulinyl-a-D-manno-pyranosyl-(1 ~4 )-2-azido-3,6-di-0-benzyl-2-deoxy-a-D-
wo 2014/016317 PCT/EP2013/065559 
46 
glucopyranosyl-(1 ~6)-1-0-(6-(S-benzyl)thiohexyl phosphono)-2,3,4,5-tetra-0-
benzyi-D-myo-inositol (compound 17) (31mg, 9.11Jmol, 1equiv) and 
triethylammonium 2-( ((benzyloxy)carbonyl)amino )ethyl phosphonate (compound 13) 
(14.7mg, 411Jmol, 4.5equiv) are co evaporated 3 times with 2ml dry pyridine. The 
5 residue is dissolved in 2ml dry pyridine and PivCI (8.41JL, 681Jmol, 7.5equiv) is 
added. The solution is stirred for 2h at r.t. before water (8.21JL, 0.45mmol, 50equiv) 
and iodine (12.7mg, 501Jmol, 5.5 equiv) are added. The red solution is stirred for 1 h 
and is quenched with hydrazine (1M in THF, 2271JL, 0.28mmol, 25equiv).The 
reaction mixture is stirred for 18h. The solvents are removed in vacuo and the 
1 0 residue is purified through flash column chromatography (CHCb/MeOH 
100/0-790/1 0) to yield yellow oil (25.3mg, 6.91Jmol, 76%). 
[a]o20 = + 46.0 (c =1.00 in CHCb); Vmax (neat) 3344, 2926, 2864, 2108, 1683, 1497, 
1454, 1363, 1093, 1071, 1028, 863cm-1; 1H NMR (600 MHz, CDCb) o 7.38-6.79 
(m, 1 05H), 6.23 (s, 1 H, NHCOCH3), 5.87 (d, J = 3.4 Hz, 1 H), 5.15 (s, 1 H), 5.00 -
15 3.30 (m, 90H), 3.24 (d, J = 10.3 Hz, 1 H), 3.11 (d, J = 4.6 Hz, 1 H), 3.03 (d, J = 8.0 Hz, 
1 H), 2.80 (d, J = 10.2 Hz, 1 H), 2.69 (q, J = 7.2 Hz, 12H, NCH2CH3), 2.28 (t, J = 7.4 
Hz, 2H, BnS-CH2), 1.86 (s, 1 H, NHCOCH3), 1.59 - 1.36 (m, 4H, -S-CH2-CH2-CH2-
CH2-CH2-CH2-0), 1.26- 1.11 (m, 4H, -S-CH2-CH2-CH2-CH2-CH2-CH2-0), 1.02 (t, J = 
7.3 Hz, 18H, NCH2CH3); 13C NMR (151 MHz, CDCI3) o 169.72 (NHCOCH3), 155.80 
20 (0-CO-NH), 139.25, 138.46, 138.30, 138.23, 137.98, 137.70, 137.48, 137.27, 
137.00, 136.33, 128.69, 128.25, 128.19, 128.13, 127.85, 127.79, 127.62, 127.27, 
127.13, 127.07, 126.80, 126.74, 126.54, 126.26, 125.68, 101.37, 100.31' 99.20, 
98.96, 98.52, 94.76, 81.97, 81.82, 81.78, 81.51' 80.99, 80.93, 80.86, 80.84, 80.52, 
80.17, 79.87, 79.48, 79.22, 78.90, 78.51' 77.79, 77.30, 75.92, 75.62, 74.89, 74.68, 
25 74.57, 74.19, 73.94, 73.35, 72.99, 72.41, 72.11, 71.48, 71.20, 71.01, 70.46, 69.50, 
69.23, 68.93, 67.83, 67.04, 66.60, 66.06, 65.93, 65.65, 64.95, 64.68, 64.19, 64.01' 
63.31' 63.23, 62.40, 62.26, 52.47, 51.52, 45.62, 44.66, 43.74, 36.52, 35.62, 34.73, 
31.66, 31.1 0, 30.71, 30.29 (BnS-CH2), 29.89, 29.82, 29.40, 29.06, 28.55, 28.23, 
28.08, 27.72, 27.25, 26.36, 25.59, 24.80, 23.96, 23.12, 22.28 (NHCOCH3), 9.11, 
30 8.26, 7.41, 6.56; 31 P NMR (243 MHz, CDCb) o 0.00, -1.32; m/z (ESI) Found: [M-2Hf 
, 1735.2054 C2ooH219Ns043P2S requires [M-2Hf, 1735.2077. 
Example 10: 6-0-(aminoethyl phosphono)-a-D-mannopyranosyl-(1~2)- a-D-
man nopyranosyl-( 1 ~6)-4-0-( a-D-g lucopyranosyl-( 1 ~4 )-2-deoxy-2-acetam ido-
13-D-galactopyranosyl)-a-D-manno-pyranosyl-(1 ~4)-2-amino-2-deoxy-a-D-
35 glucopyranosyl-(1 ~6)-1-0-(thiohexyl phosphono)-D-myo-inositol (compound 
4) 
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Bistriethylammonium 2,3,4-Tri-0-benzyi-6-0-(2-(N-benzyloxycarbonyl) aminoethyl 
phosphono )-a-0-mannopyranosyl-( 1 ~2)-3,4,6-tri-0-benzyl-a-0- mannopyranosyl-
5 (1 ~6)-3-0-benzyl-4-0-(2,3,4,6-tetra-0-benzyl-a-0-glucopyranosyl-(1 ~4 )-3,6-di-0-
benzyl-2-deoxy-2-acetam ido-~-0-galactopyranosyl )-a-0-manno-pyranosyl-( 1 ~4 )-2-
azido-3,6-di-0-benzyl-2-deoxy-a-0-glucopyranosyl-(1 ~6)-1-0-(6-(S-benzyl)thiohexyl 
phosphono)-2,3,4,5-tetra-0-benzyl-0-myo-inositol (compound 14) (20mg, 5.41Jmol, 
1 equiv) was dissolved in dry THF (3ml) and dry terl-BuOH (2 drops). The solution is 
10 cooled down to -78°C and approximately 1 Oml ammonia is condensed in the flask. 
Afterwards small pieces of sodium are added till a dark blue colour is established. 
Then the solution is stirred for 35 min at this temperature. The reaction is quenched 
with 2ml dry MeOH and the ammonia is blown off of using a stream of nitrogen. 
Solvents are afterwards evaporated and the residue is dissolved in 5ml water. The 
15 pH of the solution is adjusted with concentrated acetic acid to 7. Water is removed by 
freeze drying and the residue is purified using a small G25 column (1 cmx20cm) to 
yield a white solid (4.5mg, 3.01Jmol, 55%). 
Vmax (neat) 3350, 2918, 1646, 1025 cm-1; 1H NMR (400 MHz, 020) o 5.59 (d, J = 3.6 
Hz, 1 H, GlcNH2-1 ), 5.27 (s, 1 H), 5.23 (s, 1 H), 5.07 (s, 1 H), 4.99 (d, J = 3.8 Hz, 1 H, 
20 Glc-1 ), 4.60 (d, J = 8.2 Hz, 1 H, GaiNAc-1 ), 4.31 - 3.67 (m, 39H), 3.60 (dd, J = 10.1, 
3.6 Hz, 2H), 3.55- 3.39 (m, 3H), 3.35 (t, 2H), 2.83 (t, J = 7.2 Hz, 1 H), 2.61 (t, J = 7.1 
Hz, 1 H), 2.14 (s, 3H), 1.82- 1.58 (m, 4H), 1.54- 1.38 (m, 4H); 13C NMR (151 MHz, 
020) o 177.28 (amide), 105.01, 104.76 (GaiNAc-1 ), 103.91, 102.82 (Gic-1 ), 101.11, 
99.97 (GicNH2-1 ), 81.64, 79.91, 79.30, 79.25, 79.15, 78.84, 78.04, 75.70, 75.69, 
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75.39, 75.36, 75.29, 74.84, 74.61' 74.55, 74.40, 74.32, 74.08, 73.94, 73.62, 73.16, 
72.86, 72.83, 72.66, 72.58, 72.55, 72.50, 72.27, 72.18, 72.12, 72.06, 71.82, 71.62, 
69.60, 69.22, 68.87, 67.29, 64.51' 64.48, 63.77, 62.98, 62.82, 62.52, 56.58, 55.08, 
42.72, 42.67, 40.75, 35.52, 32.28, 30.88, 29.80, 29.67, 27.30, 27.18, 26.99, 26.52, 
5 26.29, 25.84, 24.96; 31 P NMR (162 MHz, 0 20) o 0.40, 0.22; m/z (ESI) Found: [M-Hr, 
1510.4612 Cs2H93N3041P2S requires [M-Hr, 1510.4564. 
Part A2 : Preparation of sulfone linked thiol functionalized GPI 
Formation of the mesilate ester with mesityl chloride and triethylamine followed by a 
10 SN2 reaction leads to bromide 19a that is substituted by the thiol linker under 
inversion of stereochemistry to generate 19. Oxidation with hydrogen peroxide yields 
the sulfone 20, which is deprotected under acidic conditions. Introduction of a 
protected phosphoethanolamine and cleavage of the levulinic ester using hydrazine 
produces oligosaccharide 21. Final hydrogenolysis yields glycan 22 ready for 
15 conjugation. The reaction scheme is shown under Figure 2. 
B Experimental data for Vaccination 
Example 11: Conjugation to a carrier 
20 Vaccines based on polysaccharides are characterized by a T-cell independent 
immune response without inducing an immunological memory. lmmunogenicity of 
polysaccharide vaccines in infants, elderly and immunocompromised patients are 
weak. Conjugation of carbohydrates to a carrier, such as a carrier protein or a 
glycosphingolipid with immnunomodulatory properties, creates a T-cell dependent 
25 immune response against the carbohydrate. As carrier protein, the nontoxic 
diphtheria toxoid variant CRM197 was used, since it has been approved as a 
constituent of licensed vaccines. 
Example 11a: Conjugation to a maleimide-modified protein (Figure 6) 
30 1 mg (17nmol) CRM197 was dissolved in 5001-JL PBS to yield a 401-JM CRM197 solution. 
3mg Sulfo-GMBS (Pierce) was dissolved in 5001-JL PBS (1.6mM, 40equiv.) and 
added to the protein solution. The solution was incubated for 2 h at room 
temperature, before it was concentrated and washed with water (4x5001JL) in an 
Am icon Ultra-0.5 ml centrifugal filter (Millipore ™ ). Afterwards 2501-Jg (170nmol) of 
35 GPI 3 was incubated with an equimolar amount of TCEP for 1 h in 5001-JL PBS. The 
GPI solution was added to the concentrated maleimide-modified CRM197 and the 
solution was incubated for 3 h at room temperature. The conjugate was purified using 
a G25 column (1 Ommx140mm, eluent 5%EtOH in water) and the fractions containing 
the protein were identified using Bradford solution. The fractions containing the 
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conjugate were pooled and the protein concentration was determined by BCA Protein 
Assay (Pierce). Finally the solution was lyophilized to yield the conjugate as a white 
solid. Purity and loading were determined via MALDI mass analysis. 
5 Example 11 b: In batch conjugation to an olefin-modified protein at 254 nm 
Compound of general formula (I) (1 0 equiv.) and olefin-modified CRM197 (1 equiv., p. 
Angew. Chern. 2007, 119, 5319) were dissolved in a quartz glass reaction vessel 
under argon atmosphere in degassed PBS at pH = 7.4. The solution was stirred for 6 
h under irradiation with light emitted by a low pressure mercury lamp (A.= 254, 77 W). 
1 0 Afterwards the solution was frozen dried and the crude material was purified using 
size exclusion chromatography (Sephadex-G25, 5% EtOH in water, 10 mmx150 mm) 
to yield the conjugates of the compound of general formula (I) covalently linked to the 
olefin modified CRM197, as white solids. 
15 Example 11c: In flow conjugation to an olefin-modified protein at 254 nm 
By using a photochemical flow reactor (Chern. Eur. J. 2013, 19, 3090) that was fitted 
with a loop of Teflon AF2400 tubing (566 1-JL), a solution of compound of general 
formula (I) (1 0 equiv.) in water (300 1-JL) was reacted with olefin-modified CRM197 (1 
equiv., Angew. Chern. 2007, 119, 5319) in water (300 1-JL) and AcOH (8 1-JL; residence 
20 time: 10 min, flow rate: 28.3 IJL/min-1 per syringe). The reactor output was lyophilized 
and the crude material was purified using size exclusion chromatography (Sephadex-
G25, 5% EtOH in water, 1 0 mmx150 mm) to yield the conjugates of the compounds 
of general formula (I) covalently linked to the olefin modified CRM197 as white solid. 
25 Example 11d: In flow conjugation to an olefin-modified protein at 366 nm 
By using a photochemical flow reactor (Chern. Eur. J. 2013, 19, 3090) that was fitted 
with a loop of Teflon AF2400 tubing (566 1-JL), a solution of compound of general 
formula (I) (1 0 equiv.) in water (300 1-JL) was reacted with olefin modified CRM197 (1 
equiv., Angew. Chern. 2007, 119, 5319) in water (300 1-JL) and AcOH (8 1-JL; residence 
30 time: 30 min, flow rate: 9.4 IJL/min-1 per syringe). The reactor output was lyophilized 
and the crude material was purified using size exclusion chromatography (Sephadex-
G25, 5% EtOH in water, 10 mmx150 mm) to yield the conjugate of the compound of 
general formula (I) covalently linked to the olefin modified CRM197 as white solid. 
35 Example 11e: Conjugation to a a-iodoacetamide-modified protein 
Conjugation of the compound 4 to CRM197 protein is performed as described in 
Figure 8. CRM197 (1 mg, 0.017 1-Jmol) was dissolved in sterile filtered double-distilled 
water (1 ml) and transferred to an Am icon® Ultra-4 centrifugal filter unit (1 0 kDa cut-
off). To wash away the additive sucrose the solution was concentrated to 200 1-JL, 
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sterile filtered double-distilled water (800 1-JL) was added and the solution was 
concentrated again to 200 1-JL volume. Phosphate buffer (50 mM NaH2P04, pH 8.5, 
800 1-JL) was added to the solution, which was transferred to an eppendorf tube. 
Sulfo-SIAB (0.9 mg, 1.7 1-Jmol, Thermo Scientific) was added to the solution, which 
5 was agitated for 1 h under the exclusion of light. To wash away unreacted linker the 
solution was concentrated to 200 1-Jl. Sterile filtered double-distilled water (800 1-JL) 
was added and the solution was concentrated again to 200 1-JL volume. This step was 
repeated one time. Afterwards, PBS sodium phosphate (pH 8.5, 500 1-JL) was added 
to the solution, which was transferred to an eppendorf tube. Compound 4 (250 1-Jg, 
10 0.165 1-1mol; in 250 1-JL double-distilled water) that was already incubated for 1 h with 
an equimolar amount of TCEP·HCI (tris(2-carboxyethyl)phosphine hydrochlorid, 
Thermo Scientific) was added to the solution. The reaction mixture was agitated for 3 
h under the exclusion of light, before a cysteine solution (30 1-JL, 310 mM) was added 
to quench unreacted iodoacetamine groups. The conjugate was concentrated again 
15 to 200 1-JL volume. Sterile filtered double-distilled water (800 1-JL) was added and the 
solution was concentrated again to 200 1-JL volume. This step was repeated one time. 
Sterile filtered double-distilled water (800 1-JL) was added to the conjugate solution, 
which was divided in four aliquots of 250 1-JL each and lyophilized. The white powder 
was stored at -25°C before use. Maldi-TOF analysis shows the formation of the 
20 target conjugate and that on average three compounds 4 were covalently linked to 
one carrier protein (see Figure 9). 
Example 11f: In flow conjugation of the compound 4 to a vinyl-modified 
glycosphingolipid with immunomodulatory properties 
25 By using a photochemical flow reactor (Chern. Eur. J. 2013, 19, 3090) that was fitted 
with a loop of Teflon AF2400 tubing (566 1-JL), a solution of compound 4 (1.5 equiv.) 
in water (300 1-JL) was reacted with pentenyl modified (2S,3S,4R)-1-(a-D-
galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol (1 equiv.) in water (300 
1-JL) and AcOH (8 1-JL; residence time: 10 min, flow rate: 28.3 IJL/min-1 per syringe) 
30 (see Figure 10). The reactor output was lyophilized and the crude material was 
purified using size exclusion chromatography (Sephadex-G25, 5% EtOH in water, 1 0 
mmx150 mm) to yield the conjugate of compound 4 covalently linked to the pentenyl 
modified (2S,3S,4R)-1-( a-o-galactopyranosyl )-2-hexacosanoylam inooctadecane-3,4-
diol as white solid. 
35 
Example 12: Immunizations with the conjugate consisting of compound 3 
covalently linked to CRM191 protein 
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Three female BALB/c mice were immunized s.c. with 35 IJg conjugate, prepared as 
described in example 11a, in Freund's complete adjuvant. All mice were boosted two 
times with 351-Jg conjugate in Freund's incomplete adjuvant in two-week intervals. 
After the second immunization, serum was collected and the antibody titer (total lgG) 
5 was determined by microarray six weeks after the first immunization. The results are 
shown in Figure 3. 
Example 13: Detection of T. gondii GPis by indirect immunofluorescence 
Extracellular tachyzoites collected from cell culture supernatants were fixed with 4% 
10 (w/v) paraformaldehyde in PBS for 30 min. Cells were washed three times with PBS, 
and incubated for 1 h with mice sera raised against compounds 3 or 4 diluted to 100 
in PBS, 1 0% BSA. Cells were washed three times with PBS before incubated for 1 h 
with secondary FITC-conjugated anti-mouse immunoglobulin antibody 
(DakoCytomation, Glostrup) containing 10% BSA and washed finally three times with 
15 PBS. After three final washes with PBS, aliquot were spotted on microscope slides 
followed by a glass cover slides, mounted in Fluoroprep (Dako) and recorded by 
using a 1 OOx Plan-NeoFiuar oil objective lens with NA 1 .30 using an Axiophot 
microscop (Zeiss). The results are shown in Figure 4. 
20 Example 14: Immunizations with the conjugate consisting of compound 4 
covalently linked to CRM191 protein. 
To evaluate the immunogenic properties of the conjugate consisting of compound 4 
covalently linked to CRM197 protein, obtained as described at example 11 e, BALB/c 
mice were immunized and boosted two times with 35 IJg conjugate (in each case) in 
25 Freund's incomplete adjuvant in two-week intervals. The conjugate proved 
immunogenic in all mice and immunoglobulin (lg) class-switching and affinity 
maturation were detected by carbohydrate microarray analysis (see Figure 11A). lgG 
antibodies against compound 4 were detected up to a dilution of 1 :1000 in sera of all 
mice six weeks after the first immunization. The nature of the lgG response was 
30 further evaluated, demonstrating that antibodies raised against compound 4 mainly 
consisted in lgG1 and lgG2a subclasses, while lgG3 was almost indetectable (see 
Figure 11 B), which is in agreement with previous results (Infect. lmmun. 1999, 67, 
4862). The high abundance of lgG2a, which exhibits strong antibody-dependent 
cellular and complement-dependent cytotoxicity, suggests that the immune response 
35 to the conjugate of compound 4 to CRM197 can induce phagocytosis or lysis of the 
parasite in vivo, assuming that the antibodies recognize the natural antigen on T. 
gondii cells. 
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Example 15: Specificity and epitope recognition of the antibody response 
against compound 4 
To address the specificity and epitope recongnition of the antibody response, 
carbohydrate microarray analysis with substructures of compound 4 was employed 
5 (see Figure 12). The immune response to all animals was highly specific towards 
compound 4, as antibodies did not recognize any of the substructures of compound 4 
(see Figure 12) at a dilution of 1: 1000. This indicates a possible conformational 
change induced by the a-GcNH2-(1-?6)-myo-lno moiety that affects the whole glycan 
4, since none of the substructures contains this element. Therefore, the structural 
10 conformation of compound 4 likely differs from the analyzed substructures, which 
could explain the preference of the polyclonal antibodies. Another explanation for 
this specificity might be that the raised antibody recognizes multiple epitopes on 
compound 4. Hence the avidity of lgGs is significantly lower when one or more 
structural features are not present. 
15 
Example 16: Recognition of the natural GPI antigen displayed on the T. gondii 
parasite by the antibodies raised against compound 4 
To confirm that the antibodies raised against compound 4 recognize the natural GPI 
antigen displayed on the parasite, T. gondii tachyzoites were incubated with serum of 
20 immunized mice and analyzed with immunofluoresecence (IF) confocal microscopy 
(see Figure 13). The antibodies bound to the surface of the parasite and showed 
preferential localization of the GPI containing the additional a-glucose in the side 
chain at the apical end of the cell. In contrast, antibodies binding to the parasite in 
sera of mice before immunization could not be detected. These results indicate that 
25 the GPI containing the additional a-glucose in the side chain potentially plays a role 
in the formation or function of the apical complex, which is essential for invasion of 
host cells and plays a critical role during replication of T. gondii. Tachyzoites secrete 
factors for attachment, invasion and formation of the parasitophorous vacuole, which 
is surrounding and protecting the parasite inside the host cell from endocytosis, in a 
30 regulated fashion from the apical region. Blocking the site of attachment with 
opsonizing antibodies directed against the GPI structure containing the a-Gic in the 
side chain and clustering of this antigen could disturb the organization of the apical 
membrane leading to inhibition of the cell invasion. This dual mechanism of action 
has great potential to induce sterile immunity against T. gondii 
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Claims 
1. Compound of general formula (I) 
NH 
0==\ 
OH 
HO 
5 
(I) 
wherein 
R represents -H, -CH3, -C2Hs, -C3H7, -CH(CH3)2, -C4Hg, 
1 0 -CH2-CH(CH3)2, -CH(CH3)-C2Hs, -C(CH3)3, -CsH 11, -CH(CH3)-C3H7, 
-CH2-CH(CH3)-C2Hs, -CH(CH3)-CH(CH3)2, -C(CH3)2-C2Hs, 
-CH2-C(CH3)3, -CH(C2Hs)2, -C2H4-CH(CH3)2, -C6H13, -C3H5-CH(CH3)2, 
-C2H4-CH(CH3)-C2Hs, -CH(CH3)-C4H9, -Ph, -CH2-Ph, or 
OH 
HO 0 
HO 
15 
5 
10 
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R1 and R4 represent independently of each other -OH or -OP(O)(OH)-O-
X-NH2; 
R3 represents -H, -OH, -NH2, 
-NHCOCH2CH2CH3, or -N3; 
R5 and R6 represent independently of each other -H, -L-SH, 
-(C2H40),CH2-SH or -(C2H40),C2H4-SH and R5 and R6 cannot be 
simultaneously -H; 
15 L represents a linker; 
and r is an integer from 1 to 40. 
20 2. Compound according to claim 1, wherein R represents -H. 
25 
30 
35 
3. Compound according to claim 1 or 2, wherein R1 represents -OH. 
4. Compound according to any of the preceding claims, wherein R2 represents 
-OP(O)(OR5)(0R6), 
R5 represents -H, and 
R6 represents -C6H12-SH. 
5. Method for synthesis of a compound of formula (I) according to the following 
procedures: 
a) providing a compound of the general formula (IV) 
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0 
(IV) 
R represents -H, -CH3, -C2H5, -C3H7, -CH(CH3)2, -C4Hg, 
-CH2-CH(CH3)2, -CH(CH3)-C2H5, -C(CH3)3, -C5H11, -CH(CH3)-C3H7, 
-CH2-CH(CH3)-C2H5, -CH(CH3)-CH(CH3)2, -C(CH3)2-C2H5, 
-CH2-C(CH3)3, -CH(C2H5)2, -C2H4-CH(CH3)2, -C6H13, -C3H5-CH(CH3)2, 
10 -C2H4-CH(CH3)-C2H5, -CH(CH3)-C4H9, -Ph, -CH2-Ph, or 
R3 represents -N3, and 
OPG4 
0 
I 
PG4 
PG3 to PG5 represent suitable protecting groups for hydroxyl functional 
groups; 
15 b) introducing the substituent R2 by reacting a compound of step a) with an 
acid derivative selected from H-S02(0R5') or H-P(O)(OR5')(0R6') or a 
salt thereof, 
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wherein R5' and R6' represent independently of each other -H, 
-CH2-S-PG6 , -C2H4-S-PG6 , -C3Hs-S-PG6 , -C4Hs-S-PG6 , 
-CsH10-S-PG6 , -CsH12-S-PG6 , -C7H14-S-PG6 , -CsH1s-S-PG6 , 
-CgH1s-S-PG6 , -C10H2o-S-PG6 , -CH=CH-S-PG6 , 
5 -C(=O)-(CH2)n-S-PG6 and R5 . and R6 . cannot be simultaneously -H and 
wherein PG6 is a suitable protecting group for a thiol, 
c) introducing the substituent R4 by removing PG5 or by removing PG5 and 
subsequent conversion with an acid of the formula 
H-P(O)(OH)-O-C2H4-NH(PG7) or a salt thereof, wherein PG7 is a suitable 
10 protecting group for an amine; 
d) introducing the substituent R1 by removing PG3 or by removing PG3 and 
subsequent conversion with an acid of the formula 
H-P(O)(OH)-O-C2H4-NH(PG7) or a salt thereof, wherein PG7 is a suitable 
protecting group for an amine; 
15 e) deprotecting the compound of step d) by removing the protection groups 
PG4, PG6 and PG7 resulting in a compound of formula (I) 
HO 
HO 
ts::o 
HO~O 
NH 
o=\ 
0 
0 
0 
OH 
R
3 ~0 0 OH 
R2 OH 
20 wherein R, R1 - R4 have the meanings as defined in claim 1, 
characterized in that steps c) and d) can be performed consecutively or 
simultaneously. 
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6. Method according to claim 5, wherein step c) is performed after step d). 
5 7. Method according to claim 5, wherein in steps b), c) and d) ammonium salts of 
the corresponding acids are used. 
8. Compound of any one of claims 1 -4 covalently linked to a carrier. 
10 9. Compound according to claim 8, wherein the carrier is selected from the group 
comprising a diphtheria toxoid, a mutated diphtheria toxoid, a modified 
diphtheria toxoid or tetanus toxoid. 
10. Compound of any one of claims 1 - 4 immobilized on a carrier material by 
15 covalent bonding. 
20 
11. Compound according to claim 10 wherein the carrier material is selected from 
the group comprising a glass slide, a microtiter plate, test tubes, 
microspheres, nanoparticles or beads. 
12. Compound according to any one of claims 1 - 4, 8 or 9 for vaccination against 
toxoplasmosis. 
13. Use of the compound according to any one of the claims 1 - 4, 10 or 11 for 
25 diagnosis of toxoplasmosis. 
30 
14. Use according to claim 13 for diagnosis of acute toxoplasmosis. 
15. A kit including at least the following components: 
A) A compound of general formula (I) immobilized on a carrier material by 
covalent bonding; 
B) at least one antibody: 
and 
35 C) a standard solution. 
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